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ABSTRACT
Angiogenesis in NSCLC has been identified as important therapeutic target in
combination with EGFR TKIs. However, only small incremental advancements have been made
for the use of angiogenesis inhibitors in NSCLC and it remains elusive why the inhibition of
VEGF-mediated neovascularization is not therapeutically efficacious. I present experimental
evidence that a subpopulation of NSCLC cells with EGFR TKI-induced EMT contributes toward
the attenuation of the response to EGFR TKI therapy. One of the hallmarks of cancer is
heterogeneity and I have previously demonstrated that tumor heterogeneity within NSCLC cells
lines harboring EGFR kinase domain mutations gives rise to divergent resistance mechanisms in
response to treatment. In vivo admix models are instructive in studying intratumoral heterogeneity
and in elucidating therapeutic responses and tumor-host interactions. While NSCLC cells with
acquired EGFR TKI resistance and EMT phenotype did not exhibit growth advantage in vitro, a
50% epithelial EGFR TKI sensitive and 50% mesenchymal EGFR TKI resistant admix provided
significant growth advantage in vivo assessed by caliper measurement. This preliminary result led
us to hypothesize that changes in angiogenic growth factor expression during the EMT process
might lead to the in vivo growth advantage I observed. To test the hypothesis, I utilized the
Luminex multiplex assay system to quantify secreted growth factors, cytokines, and chemokines
important in angiogenesis. I have discovered that epithelial EGFR TKI sensitive cells secrete a
significant amount of VEGF-A and cells with acquired/transient EGFR TKI resistance with an
EMT phenotype secrete substantial amount of EDN1. Using an in vitro tube formation assay, I

xii

showed that secreted VEGF-A and EDN1 in admix conditions work synergistically to promote
endothelial cell differentiation. Furthermore, this synergistic effect can be attenuated by
VEGFR2/EDNRA dual inhibition. Surprisingly, ectopic overexpression of EDN1 in EGFRmutated HCC827 cells resulted in significant growth retardation in vivo. Informed by a literature
search, I hypothesized that the presence of EDN1 in the tumor microenvironment contributes
positively to EGFR TKI resistance, possibly through the vasoconstrictive property of EDN1. I
observed that epithelial/mesenchymal admix tumors and ectopic overexpression of EDN1 in
EGFR-mutated HCC827 cells conferred significantly more resistance to gefitinib in vivo. This
result led us to hypothesize that EDN1 may reduce MVD in EGFR-mutated NSCLC tumors
leading to poor EGFR TKI penetrance in vivo. I tested this through CD31 IHC staining and MVD
calculation. I indirectly tested poor EGFR TKI penetrance by examining phosphorylated EGFR
and found maintenance of the signal in admix and mesenchymal tumors. Taken together, I suggest
that inhibition of the EDN1 signaling system may be an important component to a blood vascularbased approach to treatment of EGFR-mutation positive NSCLC.
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CHAPTER ONE
INTRODUCTION
Overview of Lung Cancer
Cancer represents one of the largest causes of death within the United States, with
an estimated one in four deaths attributed to cancer related disease. Among these, lung
cancer represents the leading cause of cancer-related deaths with 222,500 new cases in
2017 alone and an estimated 155,870 cases resulting in the death of the patient in the same
year[1]. Since the late 1980's, incidence of lung cancer has generally decreased although
this decline has varied among the several histologically defined sub- types. While
squamous, large and small cell lung carcinoma rates have declined during this period, the
incidence of lung adenocarcinoma remains stable among male patients and has increased
among women and shows large racial variances[2].
Lung cancer is histologically divided into two main sub-types; SCLC and NSCLC.
SCLC typically originates in the lung bronchi and is a fast-growing cancer which
commonly metastasizes early in development and represents approximately 10% of all lung
cancer cases. NSCLC represents approximately 85-90% of all lung cancer cases and is
divided into 3 sub-types. Squamous cell carcinoma generally originates within the center of
the lung and is common among smoking patients. Large cell carcinoma can originate in
any area of the lung and is characterized as a fast-growing cancer. Adenocarcinoma
generally originates in the outer sections of the lung and is a broadly slow-growing cancer.
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Additionally, adenocarcinoma is most commonly seen in smokers although it is the most
common type of lung cancer among non- smokers as well[3].
Based on the metastatic status of the cancer, lung cancer is typically divided into four
stages. Stage I is characterized by a small (<3cm) tumor which is localized to one lung. Stage
II is characterized by a larger tumor (>5cm) which has spread to local lymph nodes. Stage III
involves a tumor which has spread to distant lymph nodes. Stage IV represents the most
advanced cases of lung cancer and involves a large tumor (>7cm) which has metastasized to
both lungs, into pleural effusion or into a different tissue in the body[4]. Stage IV lung cancer
is commonly referred to as advanced stage or metastatic lung cancer.
The staging diagnosis is used to determine the treatment regimen for the patient.
Stage I and stage II lung cancers are most often treated with surgical resection of either the
affected lobe of the lung or wedge resection. Depending on the risk factor of the resected
tumor, adjuvant chemotherapy or radiation therapy may be prescribed. Resected tumors are
commonly tested for the presence of cancer cells at the margins of the section. If positive
margins are seen, another surgery or chemotherapy is commonly prescribed. Stage III is
commonly treated with a combination of chemotherapy, radiation therapy and surgery.
Stage IV lung cancers represent the most difficult to treat since the cancer has achieved a
large tumor size and metastasized to distant parts of the body. This is also the stage at
which most cases of lung cancer are diagnosed. These patients are often not eligible for
surgery or chemotherapy[5]. Therefore, it is important to explore developmental
therapeutics targeting the specific genetic abnormalities present in the tumor. Although
these treatments are unlikely to result in life-long remission, any extension of life or
increase in quality of life is quite valuable to the patient.
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The discovery of the oncogenic drivers in lung cancers has led to targeted therapies
which directly target the abnormal signaling pathways which lead to the propagation of
lung cancer. These therapies have been shown to effectively treat advanced stage lung
cancers with less risk of side effects compared to traditional chemotherapy. One common
driver of lung cancer is the RTK EGFR. Mutations in the kinase domain of this receptor
strongly predicts a poor prognosis and response to drugs which inhibit EGFR[6].
EGFR Kinase Domain Mutation in NSCLC
EGFR is a membrane-bound surface RTK. RTKs have been shown to have critical
roles in normal cell signaling and have also been implicated in the progression of many
types of cancer[7]. RTKs are a part of the larger family of protein tyrosine kinases which
includes receptor tyrosine kinases which possess a trans-membrane domain and nonreceptor tyrosine kinases which lack trans-membrane domains[8].
EGFR is a member of the ErbB family of receptors. The ErbB family contains four
related receptor tyrosine kinases: ErbB1 (EGFR), ErbB2 (HER2), ErB3 (HER3) and ErbB4
(HER4). This family of receptors is known to be over-expressed in several cancers
including NSCLC and breast cancer. EGFR has been consistently shown to be overexpressed in 40-80% of NSCLC patients depending on the histological classification of the
disease[9]. EGFR has been shown to be activated by several ligands including EGF, TGFα, amphiregulin, heparin-binding EGF, and betacellulin[10]. Binding of EGFR to its
ligands results in the homo- or hetero-dimerization with other ERBB family receptors
leading to internalization and auto- phosphorylation of the receptor by the tyrosine kinase
domain. Phosphorylated EGFR serves as a scaffold for the binding of signal transduction
proteins such as Grb2 which then leads to an intracellular signaling cascade involving
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down-stream proteins such as Ras[11]. The MAPK, PI3K, the AKT pathway and the STAT
pathway represent four major signaling cascades activated by EGFR activation[12]. These
pathways are known to regulate gene expression, inhibition of apoptosis, angiogenesis and
cellular proliferation leading to the development of malignancy[13]. Although it was
originally believed that EGFR signaling was distinct from angiogenesis, a link between
angiogenesis and EGFR signaling pathways has been described through the EGFRdependent stimulation of VEGF-A, a major inducer of angiogenesis[14].
A common driver of NSCLC disease is activating kinase domain mutations in
EGFR which occurs in 10-15% of Caucasian patients and 35% of Asian patients[15],
KRAS which occurs in 40% of Caucasian patients and 10% of Asian patients[16], or ALK
which occurs in 7-10% of all NSCLC patients[17]. These mutations cause the cell to
become dependent on the mutated signaling pathway and renders the tumor exquisitely
sensitive to inhibition of their respective mutated pathways, a phenomenon known as
oncogene addiction. In oncogene addiction, pro-apoptotic signaling generally increases as a
response to increased pro-survival signaling by the mutated oncogenic driver. The use of
targeted inhibitors results in the removal of oncogenic driver signaling leading to cell death
through up-regulated pro-apoptotic signaling. This phenomenon is known as oncogenic
shock[18]. Activating EGFR mutations commonly occur within exons 18-21, which code
for a portion of the kinase domain. Around 90% of EGFR exon 18-21 mutations consist of
exon 19 deletions or exon 21 point mutations resulting in a constitutively active
receptor[19]. The activating mutations commonly seen in EGFR are commonly localized to
the p-loop, a set of residues which contributes to holding the receptor in the inactive state.
In the wild-type receptor, the p-loop interacts with a c-helix regulatory domain to hold the
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receptor in the inactive state. Point mutations such as the common L858R or G719S
substitutions occur within this p-loop and disrupt interactions with the regulatory c-helix.
This causes the receptor to adopt a conformation similar to the activated wild-type
receptor. The increased sensitivity of EGFR with activating mutations such as L858R to
EGFR TKIs has been attributed to increased van der Waals interactions between the drug
and an aspartic acid residue in position 855. In the wild-type receptor, this residue is
pointed away from the ATP binding cleft but in the context of a p-loop point mutation such
as L858R, changes in receptor conformation result in ASP855 being rotated toward the
ATP binding cleft resulting in stronger binding between the receptor and drug[20, 21]. In
the more common case of EGFR exon 19 deletions (44% of all EGFR activating
mutations)[22], residues 746-750 are absent. These residues localize to the regulatory chelix domain. The deletion of these residues disrupts the interaction between the c-helix
and p-loop leading to constitutive EGFR activity by forcing the receptor to adopt a
conformation similar to the activated wild-type receptor. Like exon 21 point mutations, this
type of mutation results in an increased affinity for EGFR TKIs and reduced affinity for
ATP[23].
The first drugs to target this pathway were the receptor TKIs gefitinib and
erlotinib[16]. These drugs are reversible ATP competitive inhibitors and NSCLC cells
harboring EGFR kinase domain mutations are exquisitely sensitive to the drugs due to their
oncogene addiction[15]. Furthermore, adverse side effects from the usage of EGFR TKIs has
been shown to be minimal. In 2004, an evaluation of safety and efficacy of the EGFR TKI
gefitinib was conducted among 31 Chinese advanced NSCLC patients which had progressed
following systemic chemotherapy. It was found that gefitinib was well tolerated as
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administered by a daily oral tablet (250mg) and adverse events were generally mild (grade 1
or 2) and reversible. The most frequent adverse effects in this study were diarrhea and acne
form rash. The tumor response rate in this study was 35.5% and the median overall survival
was 11.5 months[24]. Due to these results and other agreeing studies, gefitinib has been
approved as a safe and effective treatment for advanced stage NSCLC with positive EGFR
activating mutations.
Unfortunately, response to EGFR TKI is not universal. Primary resistance occurs
through several avenues and acquired resistance can emerge due to secondary mutation
(T790M) in EGFR[25], the up-regulation of the RTK MET[26], the transformation of
NSCLC cells into a SCLC phenotype or through EMT[27].
Resistance to EGFR TKI Treatment
Primary resistance to EGFR TKI treatment is commonly defined as tumor
insensitivity during first-line administration of EGFR TKIs. Although the mechanisms
behind EGFR TKI primary resistance are not well understood, mutations have been
identified which lower the binding affinity of EGFR toward TKI molecules. The most
frequent mutations which result in primary resistance are those represented by an exon 20
insertion. These mutations exist as roughly 1-10% of all EGFR mutations and represent
mutations within the N-terminus of EGFR (M766 to C775) and most commonly, mutations
concentrate within the C-helix (A767 to C775) region. This region is important for the
manipulation of ATP by the kinase domain of EGFR into the correct orientation for
catalysis.
Another important mutation implicated in primary EGFR TKI resistance is represented
by the variant III in-frame deletion of exon 2-7 which code for the extracellular domain of
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the receptor. Interestingly, this mutation prevents EGFR from binding to its ligands such as
EGF. Although currently debated, it is thought that this mutation results in structural
changes in EGFR which affect the conformation of the ATP-binding pocket, preventing
EGFR TKI drug binding. This mutation is present in 5% of SCC and has been shown to
affect TKI resistance in vitro[28].
Primary resistance may not only occur due to mutations in EGFR but also due to
genetic alterations within EGFR down-stream signaling members. Treatment by EGFR
TKIs results in the induction of the apoptosis signaling cascade leading to the death of
the cell[29]. An important pro- apoptotic protein is the Bcl-2 family member, BIM. BIM
functions by inhibiting anti-apoptotic Bcl-2 family proteins at the mitochondria or by
activating the pro-apoptotic protein BAX[30]. Patients with BIM deletion mutations or
low levels of BIM mRNA have been associated with a poor response to EGFR TKI
treatment[31].
Acquired Resistance
Treatment with EGFR TKIs generally elicits a strong response among NSCLC
patients harboring EGFR activating mutations but drug resistance typically develops within
6-18 months of treatment[32]. This acquired resistance to EGFR TKIs greatly reduces
patient progression-free survival in advanced stage NSCLC[33]. It is important to study the
underlying genetic and expression level changes which occur during the acquisition of
resistance in order to design treatments which can treat patients with acquired EGFR TKI
resistance.
The most common route to acquired resistance is through the T790M mutation in
exon 20 of EGFR. This mutation represents approximately 50% of all acquired resistance
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cases[25]. This mutation occurs within the ATP-binding pocket of EGFR and results in an
increased affinity for ATP and a decreased affinity for first-generation EGFR TKIs[25]. In
2005, a family with a germ line T790M mutation was shown to have a predisposition to
lung cancer suggesting a possible link between the T790M mutation and tumor growth
advantage in the absence of selection by EGFR TKI treatment[34]. This predisposition is
most likely explained by the increased affinity of EGFR harboring T790M for ATP
resulting in increased EGFR signaling. While the T790M mutation results in decreased
affinity for first-generation EGFR TKIs such as gefitinib or erlotinib, patients harboring
this mutation remain sensitive to next-generation irreversible EGFR inhibitors such as
afatinib or dacomitinib[35]. Clinical trials have been performed with these drugs and
adverse effects were generally limited to diarrhea and skin rash. While the development of
these drugs were designed specifically for patients harboring the T790M mutation, the
response to these drugs in phase II clinical trials was modest compared to first- generation
EGFR TKIs[36]. Therefore, it has become clear that further research will be required to
overcome acquired resistance due to the T790M mutation.
The transmembrane receptor tyrosine kinase MET has also been implicated in
acquired resistance to EGFR TKI treatment. MET is a single-pass transmembrane tyrosine
kinase receptor which is important in normal functions such as embryonic development and
wound healing. The only known ligands for this receptor are HGF and its splice
variants[37]. Abnormal MET amplification has been shown to correlate with a poor
prognosis in several cancer types including lung, breast, kidney, liver and brain[38]. MET
activation by HGF leads to phosphorylation of the tyrosine residues T1234, and T1235.
These phosphorylated residues interact with several signal transduction proteins ultimately
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feeding into the MAPK, PI3K and STAT signaling pathways leading to increased cell
growth and survival. In NSCLC, MET amplification has been implicated in approximately
20% of EGFR TKI resistance cases[39] and therefore represents a major pathway of
acquired resistance to EGFR TKI therapy. Because of this, several clinical trials have been
performed with dual EGFR/MET inhibitors as a primary treatment of advanced stage
NSCLC. In 2010, a phase II clinical trial exploring dual MET/EGFR inhibition using the
MET inhibitor, ARQ197 and the EGFR TKI erlotinib was performed. PFS was seen to be
enhanced within patients receiving dual inhibitor treatment and was particularly effective
in patients with non-squamous histology, K-RAS mutation, and EGFR wild-type status.
Adverse side effects were not seen to be significantly increased among patients receiving
dual inhibitor treatment compared to single arm treatment and were limited to rash, fatigue,
diarrhea and nausea[40]. Although an improvement in patient outcome was seen among
those receiving dual MET/EGFR inhibitor therapy, escape from drug sensitivity was seen
among a sub-population of patients implicating other resistance mechanisms as important
in EGFR TKI insensitivity[40].
The ErbB family member HER2 has also been implicated in acquired resistance to
EGFR TKI treatment. In 2012, Takezawa et al. reported HER2 amplification in 12% of
tumors with acquired resistance to EGFR TKIs compared to only 1% of untreated lung
adenocarcinomas[41]. Similar to MET amplification, HER2 amplification has been seen to
activate the same down-stream signaling cascade as EGFR signaling involving the MAPK,
PI3K and STAT pathways[42]. With this information, a clinical trial was reported by
Janjigian et al in 2014 assessing dual therapy using the anti-EGFR antibody Cetuximab and
the second generation EGFR TKI afatinib[43]. Afatinib has been shown to effectively inhibit
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EGFR receptors harboring the T790M mutation as well as the HER2 receptor[44].
The study showed a similar response rate in patients harboring the T790M mutation
compared to T790M negative tumors. The authors contributed the similar response rates
between these two cohorts to HER2 amplification in T790M-negative responding patients
and identify HER2 as an important target in Afatinib therapy[43]. Therefore, HER2
amplification has been identified as an important mechanism of acquired resistance in
EGFR activating mutation positive NSCLC tumors[45].
As well as the previously discussed mechanisms, IGF- 1R expression has also
been shown to be associated with a poor prognosis in NSCLC patients treated with EGFR
TKIs. Additionally, the expression of IGF-1R has been shown as a negative prognosis
biomarker in NSCLC patients[46]. Through over-expression and knock out models, it has
been shown that IGF-1R does not exhibit its prognostic effects through proliferative or
survival signaling pathways such as the MAPK and AKT pathways respectively[47]. In
light of this result, alternate pathways must be explored. Recently, Varkaris et al. showed
a ligand- independent activation of the MET receptor through IGF-1R activation[48]. At
this point in time, the most supported mechanism of EGFR TKI resistance mediated
through IGF-1R amplification has been through trans-activation of other relevant
receptors[49] and may explain why a direct link between IGF-1R expression and EGFR
TKI resistance has not been shown.
Aside from genetic mutation, phenotypic-mediated acquired resistance has been
shown in tumors which have developed acquired resistance to EGFR TKIs. One important
mechanism has been identified as the histological conversion of NSCLC to SCLC. This
conversion was first seen in 2006 in which an EGFR mutant positive adenocarcinoma
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patient showed tumor response to EGFR TKI therapy for 18 months but following disease
progression, a second biopsy showed a SCLC histology harboring the original EGFR
activating mutation[50]. Following this observation, several other cases of NSCLC to
SCLC transformation have been identified[51, 52]. It has long been understood that
p53/RB1 loss has an important role in the tumorigenesis of SCLC and one study showed
that all SCLC tumors tested showed either a mutation or loss of RB1 expression[53].
Furthermore, an analysis of repeat biopsy samples acquired from EGFR TKI treated
NSCLC patients harboring a SCLC conversion showed a 100% rate of RB1[50] loss
further implicating RB1 loss as an important event in SCLC conversion.
Taken together, the conversion from a NSCLC histology to a SCLC histology has been
supported as an important mechanism to acquired resistance to EGFR TKI treatment in a
subset of NSCLC patients.
An additional important phenotype-mediated acquired resistance mechanism to
EGFR TKIs has been shown in tumors harboring a sub-population of cancer cells
expressing mesenchymal marker proteins such as CD44, N-Cadherin, and Vimentin[27,
54]. These marker proteins are well known to be up-regulated during EMT and have been
associated with poor response to EGFR TKI therapy. The EMT process also commonly
results in cancer cells with increased capabilities for invasion and metastasis as well as
stem-like properties. It has been shown that the EMT process can be induced in NSCLC
cell lines by chronic exposure to EGFR TKIs[55]. This process will occur in vitro over an
approximately 6-month period[55]. This is also the time frame in which acquired EGFR
TKI resistance occurs in NSCLC patients undergoing EGFR TKI treatment, supporting the
view that EMT contributes to EGFR TKI acquired insensitivity[56]. In support of this
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view, Cao et al. performed a statistical analysis in the CICAMS and TCGA dataset
correlating EMT signature genes with a significantly worse overall survival[23]. Moreover,
Uramoto et al. showed that nearly half (44%) of analyzed human EGFR TKI resistant
NSCLC tumors show a down-regulation of epithelial markers coupled with the upregulation of mesenchymal markers[57]. The localization of mesenchymal cells within the
tumor has been shown to be concentrated within the invasive front of the tumor while cells
which follow behind typically show epithelial traits and maintain extensive cell-cell
adhesion properties[58, 59]. Within the tumor mass, it has been proposed that cells which
maintain an epithelial phenotype secrete EMT-inducing factors to surrounding cells. These
epithelial cells maintain a sub-population of mesenchymal cells spread heterogeneously
throughout the tumor[60]. Taken together, these data suggest a link between a
mesenchymal sub-population and EGFR TKI resistance in NSCLC.
EMT Overview
Epithelial cells cover the body surface and form the lining of body cavities such as
the digestive tract and lung alveoli. These surfaces typically contain minimal amounts of
extracellular matrix and exhibit an apical to basal polarity. Conversely, mesenchymal cells
make up several different cell types such as osteoblasts, adipocytes and fibroblasts. These
cells are involved in producing the non-cellular stroma which gives support to other cell
types. EMT is a process in which an epithelial cell loses its adherens junctions, polarity and
reorganizes its cytoskeleton[56]. Several transcription factors have been identified as key
players in this transition including SNAIL, ZEB1 and ZEB2 and bHLH factors[56].
Changes in the cytoskeletal complex proteins typically involves the repression of
cytokeratin and the up-regulation of vimentin expression. These changes in protein
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expression have been shown to be initiated by a combination of various pathways which
respond to extracellular cues including TGF-β[61]. Furthermore, expression of TGF-β has
been shown to be increased upon EGFR TKI treatment[55] providing a strong correlation
between the induction of EMT and EGFR TKI treatment. When EMT occurs the cell
becomes more stem-like and frequently demonstrates drug resistance, increased metastasis
and invasiveness[62]. Cells which have undergone EMT typically show reduced expression
of EGFR as well as its ligands and typically express other RTKs such as AXL[27]. Because
of these changes in expression lead to EGFR TKI resistance, EMT has been identified as an
important process in the development of drug resistance and the associated up-regulated
receptors have been identified as targets in alternative therapies.
Endothelin-1 Overview
Endothelial cells form a single-celled lining of the inner wall of the blood vessel. It
was originally believed that these cells simply form a barrier separating blood from
vascular smooth muscle cells. With the discovery of EDRF, a new avenue of vascular
research was opened focusing on the signaling capability of the endothelium. Years later, a
potent vasoconstriction-inducing peptide was isolated from bovine endothelial cell culture
supernatant and was termed EDN1. Soon after this discovery, two other isoforms of
endothelin were discovered and termed EDN2 and EDN3. The endothelins were originally
thought to work systemically to affect blood pressure although it was later found that
circulating endothelin levels are quite low and the peptide acts primarily as a local
hormone. Beyond its effect on vasoconstriction it was found that endothelin can also act as
a mitogen for endothelial cells and vascular smooth muscle cells[63]. Because of this
result, endothelin has been explored as not only a vasoconstriction-inducing factor but also
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as a factor which can induce the proliferation of endothelial and smooth muscle cells.
The endothelin signaling axis has been implicated not only in NSCLC[64] but in
other cancers such as colorectal and kidney cancer and the expression of the ligand EDN1
and the EDNRA expression has been linked to poor survival outcomes and increased disease
progression in these cancers[65, 66]. The endothelin signaling system consists of three
different peptides, EDN1, EDN2, and EDN3 and their two receptors EDNRA and EDNRB
which belong to a family of GPCRs. EDNRA shows similar affinities for EDN1 and ET-2
but a 100-fold reduction in affinity for ET-3. Conversely, EDNRB shows a similar affinity
for EDN1, EDN2 and EDN3[67]. EDNRA, EDNRB and EDN1 have been shown to be
commonly up-regulated in multiple cancer types[68, 69] and therefore I hypothesize that
EDN1 is exerting an effect on NSCLC cells and endothelial cells through EDNRA or
EDNRB. The activation of EDNRA has been shown to result in the activation of several
pathways including the mitogen activated protein kinase (MAPK), the PI3K, and PKB
pathways[70]. The activation of these pathways is known to increase the proliferation, cell
growth, and survival[71]. The activation of the EDNRA receptor has also been linked to the
activation of the non-receptor tyrosine kinase, SRC[72]. SRC has many targets within the
cell and the activation of SRC can result in the activation of RTKs such as the VEGFR1[73],
and EGFR[74]. These receptors canonically stimulate the MAPK, PI3K and PKB pathways
increasing cell proliferation, growth and survival[75, 76]. Furthermore, the inhibition of SRC
has been linked to increased E-cadherin expression and the inhibition of EMT[126]. Because
of these previous observations, I identified the endothelin signaling axis as a worthwhile
avenue to explore the pro-tumorigenic effect of the EMT phenotype.
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EDN1 and Vasoconstriction
Of the discovered endothelins, the effects of EDN1 have been most thoroughly
characterized and seen to be the most active. The role of EDN1 in normal pulmonary
function is to maintain basal vascular tone. In general, it is understood that the activation of
the KATP channel inhibits pulmonary vasoconstriction. Through the EDNRA receptor on
smooth muscle cells, EDN1 has been shown to inhibit the activation of the KATP channel
leading to pulmonary vasoconstriction. Additionally, EDN1 has been shown to be upregulated during hypoxic pulmonary vasoconstriction and causes a vasoconstrictive effect
both in vitro and in vivo[77]. Following these observations, EDNRA blockade has been
explored for controlling vasoconstriction in humans[78].
The progression of human pulmonary arterial hypertension is known to result from
the occlusion or vasoconstriction of pulmonary vessels leading to progressive right
ventricular failure[79]. Several clinical trials have been conducted examining the effect of
EDNRA antagonists in a pulmonary arterial hypertension model. Recently, Galie et al.
showed that the addition of the EDNRA antagonist Ambrisentan to standard tadalafilmonotherapy resulted in a significantly lower risk of clinical-failure events (50%)
compared to tadalafil or Ambrisentan monotherapy[80]. Tadalafil functions by inducing
nitric-oxide release in endothelial cells through PDE5 inhibition leading to
vasodilation[81]. The increased efficacy seen in the Galie trial was attributed to the
additive effect of inducing vasodilation with tadalafil and inhibiting vasodilation with
Ambrisentan[80].
While EDN1 signaling has been thoroughly explored in cardiovascular disease[80]
and various cancer types[69, 84, 86], evidence for its role in NSCLC remains limited.
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Boldrini et al. showed that expression of EDN1 was related to a poor prognosis in NSCLC
patients[64] although the mechanism behind this remains unexplored. EDN1 signaling has
previously been shown to have a pro-angiogenic effect on cultured HUVEC cells and has
been shown to enhance the pro-angiogenic effect of VEGF in vitro[82, 83]. It would
therefore be expected that EDN1 expression in vivo would correlate with greater
angiogenesis and therefore tumor growth. This has proven to be the case in several tumor
types including ovarian carcinoma[69] and chondrosarcoma[84]. Surprisingly, antineovascularization exerted by EDN1 has also been reported in other cancer types such as
castration-resistant prostate cancer[85] and some melanomas[86]. The decreased tumor
growth in these cancers were attributed to the vasoconstrictive properties of EDN1
preventing sufficient blood flow to the tumor. Furthermore, it has been shown that
retarded tumor growth in castration-resistant prostate cancer over-expressing EDN1 can be
abrogated by treatment with vasodilators further implicating EDN1-mediated
vasoconstriction in obstructing tumor growth[85]. It is therefore an aim of this study to
explore whether EDN1 shows a pro-angiogenic or anti-angiogenic effect on tumor growth
in NSCLC. Commonly, tumor neo-angiogenesis is evaluated by calculation of MVD
within the tumor. I will utilize this technique to evaluate tumor neo-angiogenesis in a
NSCLC model.
VEGF Signaling Overview
The VEGFs are the principal regulators of blood vessel growth and function in
adulthood. These signaling peptides consist of 5 members: VEGF-A, VEGF-B, VEGF-C,
VEGF-D, and PlGF. These members exist primarily as homodimers although a heterodimer
between VEGF-A and PlGF has been reported[87]. VEGF-A was originally described by
Senger et al. in 1983 and was originally designated as VPF[88]. The function of VEGF
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family proteins is further expanded through alternative splicing. For example, VEGF-A is
naturally found in 4 isoforms, VEGF121, VEGF145, VEGF165, and VEGF189. These isoforms
show differential ability to bind ECM components such as heparin sulfate and determine
the level of VEGF-A retention at the cell surface or ECM[89]. The expression of VEGF-A
is regulated by HIF-1α, leading to increased expression in hypoxic environments[90].
VEGF-A primarily interacts with the receptor VEGFR2. VEGFR2 is a RTK family
protein with an extracellular ligand binding domain and an intracellular tyrosine kinase
domain connected by a single transmembrane domain. Like other RTKs, VEGF-A binding
to VEGFR2 induces homo- or hetero-dimerization leading to auto-phosphorylation of the
intracellular domain, allowing the phosphorylated protein complex to act as a scaffold for
the binding of down-stream signaling members[91]. VEGFR2 plays an essential role in
angiogenesis in both normal development and tumorigenesis. Shalaby et al. showed that
VEGFR2-/- mice die at E8.5 due to impaired hematopoietic and endothelial cell
development[92]. Several inhibitors of VEGFR2 have been tested in clinical trials with the
aim of inhibiting blood vessel development in the context of cancer-related disease. A
phase II clinical trial was conducted with the VEGFR2 inhibitor, ramucirumab. 140
patients with recurrent or advanced stage NSCLC were given ramucirumab as an adjuvant
treatment with traditional chemotherapy. Hypertension was reported as the primary adverse
effect. The median progression free survival was recorded as 6.5 months in patients
receiving adjuvant ramucirumab compared to 4.3 months in patients receiving
chemotherapy alone[93]. While modest improvements in patient prognosis was common
across these clinical trials, the promise of VEGFR inhibitor therapy has largely failed to
produce significant improvements in NSCLC patients.
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Given that angiogenesis is a hallmark of several types of progressive tumors, VEGF
signaling has been implicated as a potential therapeutic target. Overexpression of the
VEGFs has been found in most human cancers including NSCLC. The expression of
VEGFs in NSCLC has been linked to increased tumor recurrence, metastasis and death.
The angiogenic phenotype associated with VEGF expression is considered a hallmark of
malignancy in which increased tumor neo-angiogenesis provides a pathway to metastasis
and increased tumor growth rate[94]. Because of this, the VEGF signaling pathway has
been examined in NSCLC disease progression. To date, two antiangiogenic agents,
bevacizumab and ramucirumab have been approved for the treatment of advanced or
metastatic NSCLC as adjuvant therapy to standard first-line chemotherapy[95]. These
monoclonal antibodies target VEGF or its receptor VEGFR2 respectively. Small molecule
inhibitors of VEGFR2 have also been explored in targeting angiogenesis in NSCLC
although these drugs to date have largely failed to improve patient outcome compared to
first-line chemotherapy. The multi-target inhibitor, nintedanib, in combination with the
chemotherapy agent docetaxel, is the exception to this rule. Nintedanib targets not only
VEGF, but also PDGF and FGF signaling pathways and effectively reduces tumor neoangiogenesis and improves overall survival in patients with advanced or metastatic
NSCLC[96]. This result has generated interest in targeting VEGF signaling with other
targeted therapy such as EGFR TKIs[97].
EGFR TKI Plus VEGFR2 Inhibition in the Clinic
Because tumor neo-angiogenesis is strongly mediated by VEGF-A/VEGFR2 and
EGFR signaling strongly mediates tumorigenesis and disease progression[98-101], several
clinical trials have been performed exploring the benefit of dual EGFR/VEGFR2 inhibition
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in advanced stage NSCLC patients. The benefit of this treatment was seen to vary between
studies. A phase II clinical trial was performed with the dual EGFR/VEGFR2 inhibitor
vandetanib[102]. The aim of the study was to examine if dual EGFR/VEGFR2 inhibition
could increase the rate of pleurodesis in advanced stage NSCLC patients. The production
of pleural effusion has been identified as a marker of advanced stage NSCLC and a
common treatment is the insertion of a pleural catheter for the draining of the pleural
cavity. VEGF has also been implicated as an important signaling molecule in the
production of pleural effusion. Because of this, VEGF signaling inhibition was examined
as a potential way to target pleural effusion production. While the administered daily oral
dose of 300mg vandetanib was well tolerated among patients, the treatment did not
significantly decrease the time to pleurodesis[103].
A phase II clinical trial was reported in NSCLC patients which have progressed
after responding to treatment with either gefitinib or erlotinib using the dual
EGFR/VEGFR2 inhibitor, XL647. Patients received a daily oral dose of 300mg XL647
throughout the course of the study. A 3% response rate was seen in this study with only
one patient in the trial showing a significant response to the treatment. Patients with a
T790M mutation showed a significantly worse progression-free survival rate and the one
patient which showed a response lacked a T790M mutation. The responding patient
eventually progressed after 8 months of XL647 treatment. Since the 3% response rate did
not meet the pre-specified threshold for recommended further study, XL647 was deemed
unfit for patients which have progressed following gefitinib or erlotinib treatment[104].
Another phase II clinical trial was reported comparing the response to the EGFR TKI
erlotinib given with placebo or with the VEGFR2 inhibitor sunitinib in advanced stage
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NSCLC patients. Patients admitted into the study were those that had progressed after
receiving platinum-based chemotherapy. Patients received either 37.5 mg/day sunitinib plus
150mg/day erlotinib or placebo plus erlotinib. In the 132 randomly assigned patients, the
median PFS was 2.8 months in patients receiving the combination therapy compared to 2.0
months in those receiving erlotinib plus placebo and the overall survival was 8.2 months
compared to 7.6 months. The combination treatment was generally well-tolerated although
common adverse events such as diarrhea, rash and fatigue was seen at a greater frequency
among patients receiving the combination treatment. The study concluded that the
combination sunitinib/erlotinib therapy did not significantly increase the PFS compared to
erlotinib alone[105].
To date, no clinical trials have been conducted examining the benefit of
VEGFR2/EDNRA dual inhibition therapy. It is therefore important to explore how the
VEGF and EDN1 signaling pathways interact during NSCLC disease progression and drug
treatment.

CHAPTER TWO
MATERIALS AND METHODS
Cell Lines and Cell Culture
HCC4006 cells were obtained from ATCC.org (ATCC CRL-2871). HCC4006
harbors a mutation (L747 - E749 deletion, A750P) in the EGFR tyrosine kinase domain
which prevents the regulation of EGFR activation. The cell line was established from a 50+
year old Caucasian male with an adenocarcinoma through the collection of pleural
effusion. Cells show a population doubling time of 41 hours cultured in RPMI-1640
medium (ATCC 30-2001) supplemented with 10% FBS.
HCC4006 Ge-R cells with a mesenchymal phenotype were produced from epithelial
HCC4006 cells by former members of the Shimamura lab by exposing HCC4006 cell to
increasing concentrations of the EGFR TKI gefitinib over a 6 month period to a final
concentration of 10μmol/L resulting in a polyclonal EGFR TKI resistant cell line. EGFR
TKI resistance was confirmed by measuring cell viability after allowing cells to grow in
gefitinib-free media for 7 days followed by gefitinib treatment. Cells were then cultured
without drug and resistance to gefitinib was measured periodically[55]. Cells presented a
mesenchymal phenotype as shown by Western blot of common mesenchymal markers[56].
HCC827 cells were obtained from ATCC.org (ATCC CRL-2868). HCC827
possesses a mutation (E746 – A750 deletion) in the EGFR tyrosine kinase domain which
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prevents the regulation of EGFR activation. The cell line was isolated from the lung of a
39 year old caucasian female with an adenocarcinoma. Cells show a population doubling
time of 28 hours cultured in RPMI-1640 medium (ATCC 30-2001) supplemented with 5%
FBS.
ER23 cells were produced in a similar manner as HCC4006 Ge-R cells by previous
members of the Shimamura lab. HCC827 cells were exposed to increasing concentrations
of the EGFR TKI erlotinib up to a final concentration of 10μmol/L. Clones were isolated
and were able to proliferate normally in the presence of 10μmol/L erlotinib. EGFR TKI
resistance was confirmed by measuring cell viability after allowing cells to grow in
erlotinib-free media for 7 days followed by erlotinib treatment. Cells were then cultured
without drug and resistance to erlotinib was measured periodically[55]. Cells presented a
mesenchymal phenotype as shown by Western blot of common mesenchymal markers[56].
The 293LTV cell line was established from primary embryonic human kidney and
transformed with human adenovirus type 5 DNA. The genes encoded by the E1 region of
the adenovirus construct are expressed in these cells and allow for high protein production.
This cell line also expresses the SV40 large T antigen and Neomycin resistance genes
allowing for stable high-volume production of lentiviral particles[106]. 293LTV cells were
routinely cultured in 10% FBS DMEM supplemented with 1000μg/mL ABAM and
1000μg/mL G418.
HUVEC were obtained from Lonza (Lonza Group, CC-2935). HUVEC cells are
primary cells derived from a single donor from the resected endothelium of umbilical
cord veins. HUVEC cells were expanded in EGM media (Lonza Group, CC-3024, CC3124) and stored in liquid nitrogen. Cells were passaged by aspirating growth media and

23

rinsing cells with Lonza HEPES buffered saline solution (Lonza Group, CC-5022).
Trypsin/EDTA (Lonza Group, CC-5012) was introduced to the culture flask and allowed
to sit at 37°C for 3-5min. After cells have detached, trypsin was neutralized with Trypsin
Neutralizing Solution (TNS, Lonza Group, CC-5002). Multiple frozen aliquots of early
passage (passage 2) HUVEC cells were prepared following trypsinization by freezing in
80% EGM media, 10% DMSO, and 10% FBS and stored in liquid nitrogen.
Luminex Multiplex Assay
The Luminex human angiogenesis/growth factor magnetic bead panel 1 kit
(Millipore Sigma, HAGP1MAG-12K) was used to perform immunoassay analysis on
conditioned media prepared as previously described. In a 96-well plate, wells are rinsed
with assay buffer and 25μL of standards or conditioned media was added to each well
along with 25uL of assay buffer. 25μL of mixed beads were added to each well and
allowed to incubate at 2-8°C overnight (16-20 hours) with agitation on a plate shaker. With
the plate on a magnetic base (Millipore Sigma, #40-285), well contents are removed by
decanting followed by 3 cycles of washing using 200uL of wash buffer in each well. 25μL
of detection antibodies were then added to each well and incubated with agitation for 1
hour at room temperature. 25uL streptavidin-phycoerythrin was then added to each well
and allowed to bind for 30 minutes at room temperature. Well contents were then washed 3
times as previously described and 100μL sheath fluid was added to each well. The plate
was then analyzed on the Luminex FM3D running xPONENT® for FlexMAP™ 3D
version 4.0.846.0 SP1. Statistical significance was calculated using a one way ANOVA test
with a post hoc Student's t-test. A heatmap was produced from the resulting data using the
Morpheus web-based tool from Broad Institute. Results were log2 transformed and
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differences in expression were displayed for each analyte independently.
Cell Counting
All cell counting was performed using the Countess automated cell counter
(Thermo Fisher Scientific, 10227). Detached cells were mixed with trypan blue at a 1:1
ratio and 10uL was pipetted to a Countess cell counting chamber slide (Thermo Fisher
Scientific, C10228). Live cell count was used for seeding calculations.
Lentiviral Production and Transduction
293LTV cells were thawed from liquid nitrogen storage and seeded onto a Nunc T75 flask (Cat # 156499) in DMEM containing 10% FBS, 1000μg/mL G418, and
1000μg/mL ABAM. 48 hours prior to transfection, media was changed to antibiotic-free
DMEM containing 10% FBS. On the day of transfection, the following reagents were
combined in a sterile microtube: 4μg pLKO plasmid (target or control), 4μg ΔR8.2
plasmid, 0.5μg VSV-G plasmid. Final volume was brought to 176μL with Opti-MEM and
24μL TransIT-LT1 was added and gently pipetted to mix bringing the final volume to
200μL. Mixture was incubated at room temperature for 20-30 minutes. 293LTV cells were
trypsinized and 1×106 cells were seeded onto 60mm Corning BioCoat Collagen coated
plates. The mixture from the previous step was added drop-wise onto 293LTV cells and
gently rocked to mix. Plates were allowed to incubate at 37° C overnight. Media was
replaced with 3mL 10% FBS RMPI containing 0.58% BSA (20g/100mL +Ca2+/+Mg2+
PBS) and plates were allowed to incubate at 37° C for 72 hours. Cell culture supernatant
was collected and plates were flash frozen with LN2, allowed to thaw and cell debris and
any remaining viral particles were added to the collected supernatant. Supernatant was
centrifuged at 400xg for 3 minutes to remove cell debris. Supernatant was passed through a
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0.45μM pore SFCA membrane (Nalgene, 723-2545). Viral supernatant was stored at 4° C
and used for transduction within a week of the production. 24 hours prior to transduction,
target cells were seeded at 8×105 cells/plate in a 60mm plate to achieve 70-80% confluency
at the time of transduction including an extra plate for mock transduction. Virus containing
supernatant was mixed at a 1:1 ratio with appropriate target cell culture media and target
cell media was replaced with this mixture. Polybrene (Santa Cruz Biotechnology, SC134220) was added directly to the plate at a final concentration of 5μg/mL for HCC4006
cells and HCC4006 derived cells or 10μg/mL for HCC827 cells and HCC827 derived cells.
Media was replaced with the target cell media/virus containing supernatant every 24 hours
until 3 rounds of transduction was achieved. Following transduction, virus containing
media was removed and plates were washed twice with +Ca/+Mg DPBS and plates were
incubated at 37° C for 24 hours in proper culture media. After 24 hours, media was
changed with proper cell culture media and proper selection agent concentration was
increased until cells which underwent mock transduction died. The selection agent used for
HCC827 EDN1 over-expression models was blasticidin and the concentration was
increased to a final concentration of 5μg/mL. The selection agent used for HCC4006 Ge-R
shEDN1 knockdown model was puromycin increased to a final concentration of 5μg/mL.
Transduction was considered complete when all mock transduction cells died and final
selection agent concentration was achieved.
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shRNA Sequences Used
Target

RNAi consortium number

sequence

EDN1

TRCN0000003847

5’ – GCAGTTAGTGAGAGGAAGAAA – 3’

Non-Target N/A

5’ – GCGCGATAGCGCTAATAATTT – 3’

Remarks

Sigma

SHC-

002

Table 1: List of shRNA sequences used in study. shRNA knockdown and viral transduction
and infection were performed as previously reported[55].

Conditioned Media Preparation
HCC4006, Ge-R, HCC827, and ER23 cells were seeded onto 6-well plates at
3×105 total cells/well as a pure culture or admix. 24H after seeding, media was replaced
with 1.5ml of the proper culturing media based on cell type. Cells were allowed to grow
at 37° C for 48 hours. Conditioned media was collected after 48h and centrifuged at 400g
for 10 minutes to remove cellular debris. Cell culture supernatant was collected and flash
frozen in liquid nitrogen and stored in liquid nitrogen until assayed. Cells were lysed
using 1x Cell Lysis Buffer (Cell Signaling Technology, 9803S). Cell lysates were
analyzed for total protein concentration by BCA (Thermo Fisher Scientific, 23225) and
calculated values were used to normalize measured cell culture supernatant target protein
concentrations.
In vitro Angiogenesis
An in vitro tube formation assay was performed according to manufacturer’s
recommendations. Briefly, ibidi µ-slide angiogenesis plate (ibidi, 81501) was coated with 10
µL of reduced growth factor Matrigel (Corning, 356231) and allowed to solidify for 30
minutes at 37ºC with 5% CO2. During this time, HUVEC cells were harvested. Cells were
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counted and 50 µL of cell suspension containing 7500 cells was added to each well
containing Matrigel matrix. For conditioned media assays, HUVEC cells were suspended in
the respective conditioned media such that 50 µL of suspension contained 7500 cells and
added to each well containing Matrigel matrix. The slides were then incubated at 37ºC with
5% CO2 for 8 hours. Following incubation, Calcein AM (Thermo Fisher Scientific, C1430)
was added directly to each well to a final concentration of 1µM. Slide was allowed to
incubate at 37ºC with 5% CO2 for 10 minutes. Tube formation was captured by taking
fluorescent images with an Evos FL Cell Imaging System (Thermo Fisher Scientific,
AMF4300) with the GFP channel. Negative controls for all tube formation were performed
in EBM (Lonza Group, CC-3121) which contains proper salt and pH levels for endothelial
cells but lacks any pro-angiogenic growth factors. Positive controls in all tube formation
assays were performed in complete EGM (Lonza Group, CC-3024) which contains the proangiogenic growth factors hEGF, VEGF-A, R3-IGF-1, hFGF-β, Heparin, and FBS at
manufacturer recommended concentrations.
Image Analysis
Tube formation images were analyzed using the ImageJ Angiogenesis Analyzer
plugin provided as free software from the Gilles Carpentier Research Group[107]. The
parameters measured include total tubule length, mesh area and number of nodes.
Western Blot Analysis
Protein concentrations were determined by the Pierce BCA Protein Analysis Kit
(Thermo Fisher Scientific, 23225). Non-specific binding was blocked with 5% nonfat milk
and incubated with primary antibodies proteins of interest, E-Cadherin (Cell Signaling
Technology, 3195), N-Cadherin (Cell Signaling Technology, 13116), CD44 (Cell Signaling
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Technology, 3578), actin (Cell Signaling Technology, 8457) and EDNRA (Novus, NB600836). The membranes were then washed in PBS plus 0.1% Tween-20 and incubated with
HRP-conjugated goat anti-rabbit antibody (Cell Signaling Technology, 7074S). The
membrane was then developed with ECL reagent (Pierce, 32106) and exposed on CLXposure film (Thermo Scientific, 34089).
Murine Xenograft
All animal studies were done in accordance with IACUC guidelines under the IACUC
application “Testing Therapeutic Compounds in NSCLC” (LU # 207437). Approximately
5×106 total cells were injected sub-cutaneously into both right and left flanks of mice. The
mice were treated (oral gavage) with gefitinib (50mg/kg) daily. Tumor dimensions were
measured via external caliper measurement thrice weekly and tumor volume was calculated
(TV=(width)2 X length/2).
IHC Sample Preparation
Murine xenograft tumors were flash frozen in OCT compound (Tissue-Tek, 4583) and
stored at - 80°C until sectioning. Sections were prepared using a Cryostar NX50 OP
cryostat (MICROM International GmbH) to prepare sections of 5µM thickness. Sections
were mounted

on

Superfrost™

Plus

Gold

slides

(Thermo

Fisher

Scientific,

FT4981GLPLUS). Slides were returned to -80°C and stored until staining.
Immunohistochemical Staining
IHC staining was performed following the recommended protocol provided by Cell
Signaling Technologies for frozen tissues. Briefly, 5µM thick sections were fixed for 15
minutes in 3% formaldehyde at room temperature. Slides were washed in wash buffer (1X
TBS) twice for 5 minutes each followed by 10 minute incubation at room temperature in 3%
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H202 diluted in methanol. Slides were washed twice for 5 minutes in wash buffer followed
by incubation in blocking solution (1X TBS/0.3% Triton-X 100/5% normal goat serum).
Blocking solution was removed and immediately replaced by primary antibody specific to
the protein of interest at 1:50 dilution in blocking solution and allowed to incubate at 4°C
overnight. Antibodies used included those targeting total EGFR (Cell Signaling Technology,
4267), E-Cadherin (Cell Signaling Technology, 3195), CD44 (Cell Signaling Technology,
3578) and phosphorylated EGFR (Cell Signaling Technology, 2237). Antibody was removed
and slides were washed in wash buffer 3 times for 5 minutes each. Biotinylated secondary
antibody was added to each slide diluted 1:100 in blocking solution and allowed to incubate
for 30 minutes. ABC reagent (Vectastain, PK-6100) was prepared according to
manufacturer's specifications and allowed to stand at room temperature for 30 minutes before
use. Slides were washed in wash buffer 3 times for 5 minutes each followed by 30 minute
incubation in ABC reagent at room temperature. ABC reagent was removed and slides
washed in wash buffer for 3 times for 5 minutes each. DAB substrate was prepared according
to manufacturer's recommendation and added to each slide. Slides were allowed to develop for
2 minutes before being submersed in dH2O. Slides were counterstained with Hematoxylin per
manufacturer's recommendations. Slides were washed in dH2O twice for 5 minute each. Slides
were incubated in 95% ethanol twice for 10 seconds each. Slides were then incubated in
100% ethanol twice for 10 seconds each then repeated in xylene twice for 10 seconds each.
Coverslips were mounted using Permount Mounting Medium (Thermo Fisher Scientific,
SP15-500) and slides were allowed to dry overnight prior to imaging. Representative images
were collected in 2 untreated tumors and 4 treated tumors for each condition.
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Microvessel Density Determination
MVD was determined by the “hot spot” method to count endothelial cell-lined blood
vessels[85, 108-110]. Briefly, areas of highest microvessel density were determined to
calculate the average of 3 fields/section in two tumors/condition, Field=0.16mm2 at 200x.
CD31 was used as a marker for endothelial cells because it has been shown to be the best
marker for blood vasculature in benign and malignant tumors[111]. Since CD31 is also
expressed on platelets, macrophages, neutrophils and monocytes, I exclude any single cells
staining positive for CD31. Any CD31+ cell clusters, clearly separated from adjacent
microvessels, tumor tissue, or other tissue elements were considered as a single countable
microvessel[108]. Images were randomized prior to manual counting in order to reduce bias.
Fields with MVD closest to the average was displayed as representative images. Significance
was determined by one-way ANOVA with a post hoc student's T test for significance.

CHAPTER THREE
RESULTS
Induction of EMT in EGFR Mutation-Positive NSCLC Cell Lines
I began by ensuring the epithelial or mesenchymal status of the cell lines to be
used in our study. I found that the expression of the canonical epithelial cell marker ECadherin was down- regulated in HCC4006Ge-R mesenchymal cells compared to
epithelial HCC4006 cells, whereas canonical mesenchymal cell markers N-Cadherin and
CD44 were up-regulated (Figure 1A). Similarly, E-Cadherin expression was downregulated in mesenchymal ER23 while N-Cadherin and CD44 were up-regulated (Figure
1B). Additionally, E-Cadherin depletion using lentiviral shRNA efficiently downregulated E-cadherin and resulted in an up-regulation of N-Cadherin and CD44 (Figure
1C).
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Figure 1. Induction of EMT in EGFR Mutation-Positive NSCLC Cell Lines. A) Epithelial HCC4006 to mesenchymal
HCC4006Ge-R comparing epithelial marker E-Cadherin to mesenchymal markers N-Cadherin and CD44. B) Epithelial
HCC827 to mesenchymal ER23 comparing epithelial marker E-Cadherin to mesenchymal markers N-Cadherin and CD44.
C) Epithelial HCC827 ΔNT to mesenchymal HCC827 ΔCDH1 comparing epithelial marker E- Cadherin to mesenchymal
markers N-Cadherin and CD44.
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Admix of Epithelial HCC827 and Mesenchymal ER23 Cell Types Confers a Growth
Advantage In Vivo but No Growth Advantage is Seen in Epithelial and
Mesenchymal Admix In Vitro in Multiple Cell Lines
Soucheray et. al. showed that chronic EGFR inhibition in EGFR mutated NSCLC
cells promoted acquired EGFR TKI resistance with a mesenchymal phenotype[55]. To
develop novel therapeutics against the EGFR TKI resistant mesenchymal NSCLC cells,
our laboratory attempted developing xenograft models of the mesenchymal cells.
However, the growth of the mesenchymal NSCLC cells was significantly impaired in
vivo. Together with our collaborators, I have found that the mesenchymal NSCLC cells
need to be mixed with epithelial cells for optimal growth in vivo. Therefore, I wanted to
study why epithelial and mesenchymal cell populations need to be mixed for the optimal
in vivo growth. To this end, a subcutaneous xenograft was performed, in which epithelial
HCC827 or mesenchymal ER23 cells were injected as a pure culture or in a 50/50 admix
sub- cutaneously in an immunologically deficient murine model. I observed that
epithelial HCC827 cells successfully established a tumor in all injections. As I have
previously seen, mesenchymal ER23 cells only established tumors in 80% of injections,
and produced tumors of very limited volume (Fig.2A). Notably, a 50/50
epithelial/mesenchymal admix successfully established tumors in all injections and
exhibited a greater tumor volume at the termination of the experiment compared to
epithelial tumors (p<0.001) or mesenchymal tumors (p<0.0001). Based on this result, I
hypothesized that epithelial and mesenchymal cells are programmed to contribute to each
other for optimal tumor growth. To test the hypothesis, I have mixed epithelial HCC827
cells and mesenchymal ER23 cells in a 50/50 admix co- culture in vitro. While epithelial
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HCC827 cells initially grow faster than mesenchymal ER23 cells, no significant
difference in proliferation was observed at the end of a 6 day growth period in vitro. The
50/50 admix conditions produced no significant advantage in cell proliferation compared
to HCC827 or ER23 pure cultures at the end of a 6 day growth period (Figure 2B). To
ensure that the in vitro result is not cell lineage specific, I repeated the same in vitro
experiment using epithelial HCC4006, mesenchymal Ge-R or a 50/50, 70/30 or 30/70
admix. I observed that all admix conditions failed to produce a significant growth
advantage compared to HCC4006 cells or Ge-R cells alone in vitro (Figure 2C).

A

B)

C)

Figure 2. Admix of Epithelial HCC827 and Mesenchymal ER23 Cell Types Confer a Growth Advantage In Vivo but No Growth
Advantage is Seen in Epithelial and Mesenchymal Admix In Vitro in Multiple Cell Lines. A) Subcutaneous xenograft of a 50/50 admix of
epithelial HCC827 and mesenchymal ER23 cells demonstrate a growth advantage in vivo compared to pure epithelial (p<0.001) or mesenchymal
xenografts (p<0.0001). B) 2-D co-culture of epithelial HCC827 and mesenchymal ER23 cells do not result in a growth advantage in vitro.
Significance was determined by two-way ANOVA with a post hoc student's t-test. C) 2-D co-culture of epithelial HCC4006 and mesenchymal
HCC4006 Ge-R cells do not result in a growth advantage in vitro. Significance was determined by two-way ANOVA with a post hoc student's ttest.
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HCC827/ER23 50/50 Admix at Time of Implantation Results in an Epithelial
Dominated Tumor at 24 Days
E-Cadherin has been identified as a reliable marker of epithelial cells[112] while
CD44 has been identified as a reliable marker of mesenchymal cells[54]. Since our murine
xenograft models of admix conditions were implanted in a 50/50 ratio, and I showed that
epithelial and mesenchymal cells display no significant difference in proliferation rates in
vitro (Figure 2B,C) I hypothesized both epithelial and mesenchymal cells would continue
to maintain a 50/50 ratio within admix xenografts. To test this hypothesis, I performed IHC
staining for E-Cadherin and CD44 on frozen sections prepared from the xenograft tumors.
I found high levels of E-Cadherin expression in epithelial HCC827 tumors and high levels
of CD44 in mesenchymal ER23 tumors. I found more cells with E-Cadherin expression
than cells with CD44 expression in the admix tumors. The CD44-positive mesenchymal
cells were distributed throughout the admix tumor at a low frequency (Figure 3).

ER23

Admix

CD44
(Mesenchymal)

E-Cadherin
(Epithelial)

HCC827

Figure 3. HCC827/ER23 50/50 Admix at Time of Implantation Results in an Epithelial Dominated Tumor at 24 Days
Representative images from murine sub-cutaneous xenografts established by epithelial HCC827 cells, mesenchymal ER23 cells or a
50/50 admix stained for epithelial marker E-Cadherin or mesenchymal marker CD44. All micrographs are taken at 20x magnification.
Scale bars represent 100µm.
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The EMT Process Results in Differential Expression of Several Pro-Angiogenic and
Growth Factors
Since the increased tumorigenicity of epithelial and mesenchymal admix cells
were observed only in vivo, I sought to determine if tumor-host interaction might be the
causal factor for the observed growth advantage. I hypothesized that a change in gene
expression during EMT may be establishing a signaling pathway between the tumor and
host vasculature. To assess whether the EMT process results in a change in expression in
factors known to influence blood vasculature, I performed a Luminex multiplex assay
analyzing the concentrations of secreted factors by epithelial or mesenchymal cells into
the media in an in vitro culture over a 48 hour growth period. I assessed the concentration
of VEGF-A, EDN1, FGF-2, VEGF-C, VEGF-D, Angiopoietin-2, FGF-1, HGF, PLGF
and endoglin. I compared epithelial HCC4006, HCC827, and HCC827 shNT to
mesenchymal HCC4006Ge-R, ER23, HCC4006 O-R, and HCC827 shCDH1. I observed
that all epithelial and mesenchymal cell lines tested secreted similar concentrations of
VEGF-C, VEGF-D, FGF-1, HGF, PLGF, and endoglin. I discovered that VEGF-A
secretion was lower in all mesenchymal cell lines tested compared to epithelial cells.
Furthermore, I observed that EDN1 secretion was higher in all mesenchymal cell lines
tested compared to epithelial cells (Figure 4). While Angiopoietin-2 was significantly upregulated in HCC827 when mesenchymal phenotype was induced, the same increase was
not seen in HCC4006 with a mesenchymal phenotype. FGF-2 secretion was high in
HCC4006Ge-R or HCC4006O-R compared to epithelial HCC4006 although this result
was not observed in HCC827 cells (Figure 4). I therefore focused on the secreted
concentration of VEGF-A and EDN1.
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Figure 4. EMT Process Results in Differential Expression of Several Pro-Angiogenic and
Growth Factors. Luminex multiplex angiogenesis/growth factor multiplex assay analysis
comparing HCC4006/HCC4006 Ge-R, HCC827/ER23, HCC4006/HCC4006 O-R, and HCC827
shNT/HCC827 shCDH1. Cell culture supernatant was collected and analyzed for secreted
concentrations of VEGF-A, VEGF-C, VEGF-D, EDN1, FGF-1, FGF-2, angiopoietin-2, HGF,
PLGF and endoglin. All epithelial cell lines have been labeled with an E while all mesenchymal
cell lines were labeled with an M.
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Induction of EMT or EGFR Inhibition Results in a Significant Increase in EDN1
Secretion and Decrease in VEGF-A Secretion
I evaluated our Luminex Multiplex assay results quantitatively using a one-way
ANOVA analysis with a post hoc student's T test for significance. I found that in
comparing HCC4006 and HCC4006Ge-R there was a significant reduction in VEGF-A
secretion (p<0.001) coupled with a significant increase in EDN1 secretion (p<0.001)
during a 48 hour growth period. Furthermore, I observed no significant reduction in
VEGF-A secretion in a 50/50 epithelial/mesenchymal admix compared to epithelial alone
coupled with a significant decrease in EDN1 concentration (Figure 5A). This may be due
to EDN1 being secreted by mesenchymal HCC4006Ge-R cells and taken up by epithelial
HCC4006 cells. I sought to replicate this result in other cell lines. I saw a significant
increase in EDN1 secretion (p<0.001) coupled with a significant decrease in VEGF-A
secretion (p<0.001) in mesenchymal HCC4006O-R compared to epithelial HCC4006 cells
(Figure 5B). I also observed a significant increase in EDN1 secretion (p<0.001) coupled
with a significant increase in EDN1 secretion (p<0.001) when comparing mesenchymal
ER23 or HCC827 shCDH1 compared to epithelial HCC827 cells (Figure 5C,D). I also
observed a non-significant reduction in VEGF-A secretion when HCC827 cells were
grown in a 50/50 admix with ER23 cells while EDN1 expression was predictably found to
be at ~%50 of that of a pure mesenchymal ER23 cell culture. Because EDN1
concentrations were not depleted in our 50/50 admix condition, we used HCC827/ER23
cell lines for all in vivo studies. It remained unclear whether this change from VEGF-A to
EDN1 secretion represented an event in the EMT process or a consequence of EGFR
inhibition. To analyze this, I exposed epithelial HCC4006 to 100nM gefitinib treatment for
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72 hours. I observed that short-term gefitinib was sufficient to induce a significant upregulation of EDN1 secretion coupled with a significant down-regulation of VEGF-A
(Figure 5E).

Figure 5: Induction of EMT or EGFR Inhibition Results in a Significant Increase in EDN1 Secretion and Decrease in VEGF-A
Secretion. A) Epithelial HCC4006 showed robust levels of VEGF-A secretion and relatively low levels of EDN1 whereas
mesenchymal HCC4006 Ge-R cells secreted significantly greater concentrations of EDN1 and significantly lower concentrations of
VEGF-A (p<0.0001). No significant change in VEGF-A secretion was seen under 50/50 or 10/90 epithelial and mesenchymal coculture conditions. B) Epithelial HCC4006 and mesenchymal HCC4006 O-R cell lines exhibit a significant loss of VEGF-A secretion
coupled with a significant gain in EDN1 secretion(p<0.0001). C) Epithelial HCC827 and mesenchymal ER23 cell lines exhibit a
significant loss of VEGF-A secretion coupled with a significant gain in EDN1 secretion(p<0.0001). D) Epithelial HCC827 shNT and
mesenchymal HCC827 shCDH1 cell lines exhibit a significant loss of VEGF-A secretion coupled with a significant gain in EDN1
secretion(p<0.0001). E) 72 hour EGFR TKI treatment (100nM gefitinib) was sufficient to cause the loss of VEGF-A secretion and
gain of EDN1 secretion in epithelial HCC4006 cells. Significance was determined by one way ANOVA analysis with post hoc student
T-test.
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Epithelial/Mesenchymal Admix Conditioned Media Confers Greater Differentiation
Potential in Cultured HUVEC Endothelial Cells Compared to Epithelial or
Mesenchymal Pure Culture Conditioned Media
It has been previously shown that in vitro tube formation is enhanced under both
10nmol/L EDN1 and 1ng/ml VEGF-A when performed with HUVEC cells. These factors
demonstrated a synergistic effect leading to greater angiogenic potential when used in
combination compared to either agent alone[83]. Since I have already seen notable
concentrations of VEGF-A and EDN1 in epithelial and mesenchymal cell culture
supernatant respectively, I hypothesized that conditioned media produced from admix
conditions would contain significant levels of both VEGF-A and EDN1. If true, admix
conditioned media would offer greater angiogenic potential in a tube formation assay
compared to epithelial or mesenchymal cells grown alone. In an 8 hour tube formation
assay, the condition media from HCC4006 and HCC4006Ge-R cells grown in a 50/50
admix promoted greater tube formation potential compared to supernatants from HCC4006
or HCC4006Ge-R cells (Figure 6A). Images were captured with an Evos FL Cell Imaging
System (AMD, AMF4300) in the GFP channel. Images were analyzed using the ImageJ
Angiogenesis Analyzer plugin provided as free software from the Gilles Carpentier
Research Group[107]. A significant increase in the number of nodes (p<0.01), total tubule
length (p<0.01) and mesh area (p<0.001) was seen in HCC4006 and Ge-R cells grown in a
50/50 admix when compared to negative control EBM or HCC4006 or Ge-R cells grown in
pure culture (Figure 6B).

Figure 6. Epithelial/Mesenchymal Admix Conditioned Media Confers Greater Differentiation Potential in Cultured
HUVEC Cells Compared to Epithelial or Mesenchymal Pure Culture Conditions. A) Qualitative comparison of conditioned
media produced from epithelial HCC4006 cells, mesenchymal HCC4006 Ge-R cells, and HCC4006/HCC4006 Ge-R cells grown
in 50/50 admix. Tube formation in basal media (EMB) and fully supplemented growth media (EGM-2) has been included as
negative and positive controls respectively. Images are representative of 3 repeat experiments. Traces in green represent total tube
length; red points represent nodes, blue traces represent mesh areas. B) ImageJ angiogenesis quantification of commonly analyzed
tube formation parameters including mesh area (p<0.001), total tubule length (p<0.01) and number of nodes (p<0.01).
Significance determined by one-way ANOVA with post hoc student's t-test. Error bars represent standard error between repeat
samples.
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To test if the result that increased tube formation in supernatant from the admix cells
is due primarily to the presence of VEGF-A and EDN1, I performed a tube formation assay
in growth factor reduced EBM with either 10nM VEGF-A, 10nM EDN1 or a combination of
10nM VEGF-A and 10nM EDN1 (Figure 7A). These concentrations were calculated from
the concentrations of VEGF-A and EDN1 as measured by Luminex analysis (Figure 5). I
found that while all conditions failed to produce a significant increase in tube formation
above basal levels, a clear trend toward enhanced tube formation was present in the
combination treatment compared to either single target treatment (Figure 7B).

Figure 7. In Vitro Angiogenesis Analyzed by Tube Formation Assay. A) Qualitative comparison of tube formation in basal
EBM media supplemented with 10ng/mL VEGF-A, 10nM EDN1 or a combination of both factors. Tube formation in basal media
EMB and fully supplemented EGM-2 has been included as negative and positive controls respectively. Images are representative
of 3 repeat experiments. B) ImageJ angiogenesis quantification of commonly analyzed tube formation parameters including, total
tubule length and number of nodes. Significance determined by one-way ANOVA with post hoc student's t-test. Error bars
represent standard error between repeat samples.
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Sunitinib/Zibotentan Combination Therapy Effectively Inhibits Tube Formation In
Vitro
To further test if the increased tube formation in the conditioned media from the
admix cells are due to the effects of VEGF-A and END1, I utilized chemical inhibitors of
VEGFR2 and EDNRA, sunitinib and Zibotentan respectively, to investigate if inhibition of
VEGFR2 and EDNRA could suppress tube formation by the condition media. While
sunitinib is known to also inhibit PDGFRs and other VEGFRs, its main target is VEGFR2.
Zibotentan was chosen because it is a specific inhibitor to EDNRA. Representative images
from tube formation in untreated admix conditions, low-dose 10nM sunitinib treatment,
low-dose 100nM Zibotentan treatment, and dual drug treatment were obtained (Figure
8A). Upon quantification, I observed that low dose (10nM) sunitinib did not produce a
significant reduction in tube formation in conditioned media produced from admix
conditions. Likewise, low dose (100nM) Zibotentan did not produce a significant reduction
in tube formation in conditioned media produced from admix conditions. The combination
of 10nM sunitinib and 100nM Zibotentan significantly inhibited tube formation (p<0.01)
in admix conditioned media (Figure 8B). I therefore showed that the combination
treatment targeting both VEGFR and EDNRA as an effective inhibitor of angiogenesis in
vitro.

Figure 8. In Vitro Inhibition of Angiogenesis Analyzed by Tube Formation Assay. A) Qualitative comparison of tube
formation in conditioned media produced from a 50/50 admix of epithelial HCC4006 and mesenchymal GER cells treated with
10nM Sunitinib, 100nM Zibotentan, or a combination of the two factors, respectively. Images are representative of 3 repeat
experiments. B) ImageJ angiogenesis quantification of commonly analyzed tube formation parameters including number of nodes,
total tubule length and total mesh area. Significance determined by one-way ANOVA with post hoc student's t-test. Error bars
represent standard error between repeat samples.
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The Expression of EDNRA and Phosphorylated VEGFR2 in HUVEC Cells is Increased
Under 8H Stimulation by Admix Conditioned Media and Sunitinib Abrogates VEGFR
Phosphorylation
Since VEGF-A has been shown to primarily exhibit its pro-angiogenic effect
through the VEGFR2 receptor, I consider VEGFR2 phosphorylation as a marker of VEGFA activity[91]. While VEGF-A has been shown to strongly bind to VEGFR1, the receptor
has been shown to have a weak effect on angiogenesis[113]. I therefore focused our studies
on VEGFR2 signaling. To test whether I am effectively inhibiting VEGFR2 through low
dose 10nM sunitinib treatment, I examined VEGFR2 signaling under stimulation by
conditioned media produced from epithelial HCC4006 cells and mesenchymal
HCC4006GE-R cells grown under 50/50 admix conditions (Figure 9). I found that while
total VEGFR2 was comparable under all conditions tested, phosphorylated VEGFR2 was
up-regulated under stimulation by conditioned media produced under admix conditions or
by complete EGM which contains no VEGF-A or EDN1. Phosphorylated VEGFR2 was
abrogated by low dose 10nM sunitinib treatment when added to either admix conditioned
media or complete EGM. I observed that EDNRA levels are decreased under unstimulated
8h EBM conditions while EDNRA levels are comparable when stimulated by conditioned
media or complete EGM in the presence or absence of sunitinib treatment (Figure 9).
EDNRA, total VEGFR2 and phosphorylated VEGFR2 expression was normalized against a
vinculin loading control.
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Figure 9. HUVEC Cells Express EDNRA and Phosphorylated VEGFR2 is UpRegulated Under 8H Stimulation by Admix Conditioned Media While Being Effectively
Abrogated by 10nM Sunitinib Treatment. Western blot comparing expression of EDNRA,
VEGFR2, and pVEGFR2 under unstimulated conditions (8H basal EBM media) or
stimulation with admix conditioned media or complete growth media (EGM) with or without
10nM sunitinib.
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NSCLC Cells Lines with an EDN1 Over-Expression or Knock-Down Phenotype
maintain VEGF-A Secretion In Vitro and EDN1 Secretion was Associated With
Significantly Lower Tumor Growth
I sought to analyze the effect of EDN1 on the tumor microenvironment in vivo,
therefore, I generated a HCC827 cell line which ectopically expresses EDN1 using a pLX
lentiviral expression vector (HCC827 EDN1). I used HCC827 cells transduced with a pLX
vector lentivirus coding for flag-V5 as a control (HCC827 Flag/V5). Upon antibiotic
marker selection, I ensured constitutive EDN1 secretion in the supernatant from HCC827
pLX EDN1 cells using Luminex assay. Additionally, the secretion of VEGF-A was
maintained in these cells (Figure 10A). Interestingly, when I performed a sub-cutaneous
xenograft experiment comparing the growth of HCC827 Flag/V5 to HCC827 EDN1, I
observed that HCC827 Flag/V5 cells showed a growth advantage compared to HCC827
EDN1 as analyzed by caliper measurement (Figure 10B). To test if secretory EDN1
attenuates in vivo tumor growth, I generated HCC4006Ge-R cells with either an EDN1 or
non-target knockdown. The depletion of EDN1was confirmed in supernatants from the
engineered cells using the Luminex assay (Figure 10C). Interestingly, EDN1 knockdown in
Ge-R cells resulted in a significant increase in VEGF-A secretion compared to non-target
knockdown (Figure 10C). To further test the role of EDN1 on tumor growth rate, tumors
grown with Ge-R shEDN1 in admix with epithelial HCC4006 cells were shown to possess
a growth advantage in vivo compared to Ge-R shNT cells in admix with epithelial
HCC4006 cells (Figure 10D). Taken together, these data suggest that EDN1 is not
important in explaining why admix conditions produce a growth advantage in vivo.

Figure 10: NSCLC Cells Lines Harboring EGFR Kinase Domain Mutations Maintain VEGF-A Secretion In Vitro When
EDN1 is Either Over-Expressed or Knocked Down and Result in a Slower or Faster Growing Tumor Respectively In Vivo.
All Error Bars Represent Standard Error of Mean Between Repeat Conditions. A) VEGF-A (ns) and EDN1 (p<0.001)
secretion as measured by a Luminex multiplex assay analyzing conditioned media produced over 48h in HCC827 Flag/V5 or pLX
EDN1. B) HCC827 pLX EDN1 significantly inhibits tumor growth compared to HCC827 pLX Flag/V5 tumors (p=0.0069).
C) VEGF-A (p<0.01) and EDN1 (p<0.001) secretion as measured by a Luminex multiplex assay analyzing conditioned media
produced over 48h in Ge-R shNT or Ge-R shEDN1. D) Ge-R shEDN1 grown in admix with HCC4006 significantly potentiates
tumor growth compared to Ge-R shNT (p=0.0186)
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EDN1 Expressing Tumors Show Significantly Greater EGFR TKI Resistance In Vivo
I observed that EDN1 expression did not correlate with a growth advantage in vivo,
although it is known that EDN1 expression is a known negative prognostic marker in
NSCLC. I therefore sought to test whether EDN1 expression could positively affect EGFR
TKI resistance. I tested gefitinib sensitivity in epithelial HCC827 and gefitinib resistance in
mesenchymal ER23 cells in vitro by MTS assay (Figure 11A). I subjected HCC827, ER23,
and the admix xenograft tumors to a 6-day course of gefitinib (50mg/kg daily) treatment.
Tumor volume was calculated using external caliper measurement and upon completion of
the drug treatment, tumor volume was measured via caliper following tumor excision.
Percent residual tumor was calculated by comparing tumor volume before and after the
gefitinib treatment. I found that both pure mesenchymal and admix tumors show
significantly higher residual tumor volume following gefitinib treatment compared to
epithelial tumors (p<0.0001) (Figure 11B). I also treated HCC827 Flag/V5 and HCC827
pLX EDN1 tumors with gefitinib for 6 days and measured tumor volume after excision
from the mouse. I found that while EDN1 over-expression resulted in a slower growing
tumor (Figure 10B), the resulting tumor was more resistant to gefitinib treatment as shown
by a significantly greater residual tumor volume (p=0.0353) after 6 days of gefitinib
treatment (Figure 11D). Taken together, these data suggest that EDN1 expression
contributes to drug resistance in vivo.

Figure 11. Mesenchymal or Epithelial/Mesenchymal Admix Tumors and Tumors Overexpressing EDN1 Result in
Significantly Greater EGFR TKI Resistance In Vivo. Error Bars Represent Standard Error Between Means for All
Figures. A) Sensitivity to gefitinib treatment as measured by MTS assay comparing HCC827 to ER23. B) Subcutaneous xenograft
of mesenchymal ER23 and 50/50 admix of HCC827 and ER23 demonstrates significant drug resistance in vivo compared to pure
epithelial xenografts (p<0.0001). C) Sensitivity to gefitinib treatment as measured by MTS assay comparing HCC827 pLX
Flag/V5 to HCC827 pLX EDN1. D) Percent tumor volume change following 6-day gefitinib treatment (50mg/kg daily)
(p=0.0353).
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The Presence of EDN1 Secreting Cells in Admix Tumors or an Over-Expression Model
Promotes Significantly Reduced Microvessel Density
Because I observed significant drug resistance in tumors with an EDN1 secreting
mesenchymal sub-population in vivo but not in vitro, I performed a literature search to
identify tumor-host interactions involving EDN1 contributing to drug resistance. It has
been previously shown that a lower MVD correlates with drug resistance in NSCLC[125].
I hypothesized that epithelial/mesenchymal admix conditions and mesenchymal xenografts
would result in a tumor with lower MVD compared to epithelial tumors due to the
vasoconstrictive properties of EDN1. By constricting local vessels, EDN1 may be limiting
nutrient availability to the epithelial sub-population of the tumor. This effect would lower
available VEGF-A secretion by epithelial cells and lead to lower MVD. Upon drug
treatment, a diminished MVD may be leading to poor drug perfusion and an increase in
apparent drug resistance in vivo. To explore this, I performed sub-cutaneous xenografts
using epithelial HCC827, mesenchymal ER23 or a 50/50 admix. I prepared frozen sections
from the resulting tumors and performed IHC staining for CD31. I chose to use CD31 as a
marker for endothelial cells because it has been shown to be the best marker for blood
vasculature in benign and malignant tumors[111]. Since CD31 is also expressed on
platelets, macrophages, neutrophils and monocytes, I exclude any single cells staining
positive for CD31. I considered any CD31+ cell cluster, clearly separated from adjacent
microvessels, tumor tissue, or other tissue elements as a single countable microvessel[108].
I found a significant decrease in MVD in mesenchymal ER23 or HCC827/ER23 50/50
admix tumors compared to epithelial HCC827 tumors (p<0.0001) (Figure 12A). I then
sought to isolate the effect of EDN1 expression through an EDN1 knockdown model. I
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performed sub-cutaneous xenografts using epithelial HCC4006 cells grown alone or in a
50/50 admix with mesenchymal Ge-R cells with either an EDN1 knockdown or a nontarget knockdown (Figure 12B). Tumors produced from HCC4006 cells grown in admix
with EDN1 secreting HCC4006Ge-R shNT cells (Figure 10C) show a significant decrease
in MVD compared to HCC4006 (p<0.001). This effect was abrogated by lentiviral shRNA
knockdown of EDN1 (Figure 12B). It is important to note that most areas of high vessel
density were identified around the edges of the tumor section. This is most likely due to the
short growth time of these tumors relative to their analog within a patient. Blood
vasculature growth typically begins at the margins of a tumor and proceeds inward[124]. If
a longer growth time was permissible, I would expect areas of high blood vessel density to
be present within the tumor body as well as margins.

Figure 12. Epithelial/Mesenchymal Admix Conditions Results in Significantly Lower Blood Vessel Density Which Can be
Abrogated Through Knockdown of EDN1 in Mesenchymal Cells. Significance was Determined by One-Way ANOVA With
a Post Hoc Student’s T-Test. Scale Bars Represent 100µm. Error Bars Represent Standard Error Between Means.
A) Representative images from tumors produced from epithelial HCC827, and mesenchymal ER23 cells grown alone or in a
50/50. Images taken at 20x magnification. MVD was calculated by the “hot spot” method as previously described. B)
Representative images from tumors produced from epithelial HCC4006, and HCC4006 cells grown in admix with mesenchymal
Ge-R cells with a non-target or EDN1 shRNA knockdown. Images taken at 20x magnification. MVD was calculated by the “hot
spot” method as previously described.
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Phosphorylated EGFR is Maintained in Gefitinib Treated Mesenchymal and Admix
Tumors
Phosphorylated EGFR has been accepted as a reliable pharmacodynamics marker
for EGFR TKIs. Consequently, I could assess the bioavailability of EGFR TKIs in the
tumor by measuring the level of pEGFR[114]. I found that epithelial/mesenchymal admix
xenograft tumors are significantly more resistant to EGFR TKIs than epithelial xenograft
tumors (Figure 11B). I first wanted to assess if EGFR TKIs were effectively delivered to
admix xenografts by measuring p-EGFR by IHC staining. To produce representative
images, 2 tumors from untreated conditions and 4 tumors from treated conditions were
examined. I performed IHC staining for phosphorylated EGFR on tumor sections prepared
from epithelial HCC827, mesenchymal ER23 or admix tumors. I found that phosphorylated
EGFR was effectively reduced by gefitinib treatment in epithelial HCC827 tumors while
phosphorylated EGFR was maintained in mesenchymal ER23 and admix tumors (Figure
13). I also examined total EGFR expression by IHC staining in the same set of samples. I
found that total EGFR expression was comparable across all untreated conditions. Among
gefitinib treated tumors, epithelial HCC827 tumors show a disruption of solid structure and
a down-regulation of EGFR while mesenchymal ER23 tumors and admix tumors display a
maintenance of total EGFR expression (Figure 14). The disruption of a densely packed
tumor cell structure and the adoption of a spongiform morphology has been associated
with sensitivity to EGFR TKI treatment in a NSCLC model[122].

Figure 13. Phosphorylated EGFR is Maintained in Gefitinib Treated Mesenchymal and Admix Conditions. Representative
images from murine sub-cutaneous xenografts established by epithelial HCC827 cells, mesenchymal ER23 cells or a 50/50 admix
stained for phosphorylated EGFR. All micrographs are taken at 20x magnification. Scale bars represent 100µm.
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Figure 14: Total EGFR is Comparable in Untreated Conditions While Total EGFR is Maintained in Gefitinib Treated
Mesenchymal ER23 and Admix Tumors. Representative images from murine sub-cutaneous xenografts established by epithelial
HCC827 cells, mesenchymal ER23 cells or a 50/50 admix stained for total EGFR. All micrographs are taken at 20x magnification.
Scale bars represent 500µm and 100µm respectively

CHAPTER FOUR
DISCUSSION

Activating EGFR mutations in NSCLC patients allow for the use of therapies
targeting EGFR signaling. While EGFR TKI therapy is initially efficacious in most EGFR
mutation positive NSCLC patients, the disease eventually progresses after the emergence
of acquired resistance and limits the efficacy of this therapy[25]. In an attempt to
circumvent the limitations of EGFR TKI therapy, several clinical trials were performed
attempting to limit the effect of tumor neo-angiogenesis in NSCLC. These trials focused on
the inhibition of VEGFR2 signaling to prevent neo-angiogenesis, a prerequisite for the
tumor colonization upon metastasis. Unfortunately, the treatment combining VEGFR2
inhibitors with standard chemotherapy or EGFR TKIs show little to no survival advantage
over therapeutic regimens which do not include VEGFR2 inhibition[93, 103-105]. This
result is surprising due to the documented importance of tumor neo-angiogenesis in tumor
growth and disease progression as well as the documented VEGFR2 expression in NSCLC
tumors. Since patients showing resistance to EGFR TKI therapy also commonly present a
heterogeneous tumor, I sought to explore whether tumor heterogeneity could explain why
VEGFR2-based therapies failed in the clinic. In order to study this question, we must
understand the dynamics of how tumor heterogeneity emerges in the patient.
It has been proposed that most spontaneous tumors originate from a single
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cell[115]. While there has since been evidence to support this model[116], limitations in
tumor biopsy sampling protocols do not allow for the exclusion of a multicellular origin in
some human tumor types. Regardless of mechanism of origin, it is generally accepted that
tumor heterogeneity increases over time and in response to drug treatment in human
patients. Indeed, at time of diagnosis, the majority of tumors display heterogeneity in
regards to several morphological and physiological characteristics. These differential
characteristics often manifest in cell surface receptor expression, proliferative capacity and
angiogenic potential.
The induction of an EMT phenotype has been studied in at least two major ways.
The first involves exposing epithelial cells to increasing concentrations of EGFR TKIs over
a period of time[55]. The second involves the depletion of epithelial markers such as ECadherin by lentiviral shRNA transduction[117]. The advantage of studying EGFR TKI
resistance by EMT in cells chronically exposed to increasing doses of EGFR TKIs is that it
represents the direct in vitro analog of the EMT phenotype which emerges in patients
undergoing EGFR TKI therapy. However, off- target effects of drug treatment may result in
changes in expression independent of the EMT process. Induction of EMT by lentiviral
shRNA knockdown of E-Cadherin eliminates the possibility of EMT- independent changes
in expression, however the mechanism of induction is artificial and not seen in patients. It
is therefore imperative to study EMT mediated EGFR TKI resistance by using a multitude
of cell lines created through both processes. In order to study EMT-mediated EGFR TKI
resistance in NSCLC cells, I utilized cells with a mesenchymal phenotype produced from
chronic exposure to EGFR TKI treatment or through lentiviral knockdown of the epithelial
marker E-Cadherin. I validated the use of lentiviral knockdown and chronic drug treatment
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for the generation of NSCLC cell lines displaying a mesenchymal phenotype. The
mesenchymal properties of these cell lines form the basis of our study on EMT-mediated
tumor heterogeneity.
I initially set out to determine how epithelial and mesenchymal lung cancer cells
interact in vivo. To this end, I performed a sub-cutaneous xenograft in a murine model with
epithelial HCC827, mesenchymal ER23 cells, or a 50/50 admix. I found that admix
conditions produce tumors with greater volume compared to either epithelial or
mesenchymal cells alone. In order to determine if this effect was due to signaling between
epithelial and mesenchymal cells, I performed an in vitro growth assay using epithelial
cells, mesenchymal cells or multiple admix conditions and measured cell count over a 6
day period. I found that while admix conditions produced a growth advantage in vivo
(Figure 2A), this effect was not present in vitro (Figure 2B,C). If an interaction between
epithelial cells and mesenchymal cells could explain the growth advantage seen under
admix conditions in vivo I would expect this result to be replicated in vitro. Since I did not
see this, it suggests that the growth advantage seen in vivo may be due to tumor-host
microenvironment interaction.
One major way in which tumors are known to interact with the host is through the
blood vasculature. During excision of our xenograft tumors, it was observed that admix
tumors seemed to have greater blood vasculature compared to epithelial or mesenchymal. I
hypothesized that the interaction between admix tumors and the host vasculature may
explain why admix conditions confer a growth advantage in vivo but not in vitro. To
determine if EMT affected the expression of angiogenesis-related growth factors, I
performed a Luminex multiplex assay for 10 factors known to influence blood vasculature.
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By performing this assay on supernatants from epithelial, mesenchymal or admix cell
culture, I can measure the amount of each secreted factor. I focused on the effect of EMT
on the secretion of VEGF-A and EDN1 since these showed differential secretion in all cell
lines tested when comparing epithelial to mesenchymal cells. I found that during the EMT
process, the secretion of VEGF-A was significantly reduced while the secretion of EDN1
was significantly up-regulated (Figure 5A-D). Interestingly, in 50/50
HCC4006/HCC4006Ge-R admix conditions I found that VEGF-A secretion was
comparable to that of epithelial HCC4006 alone. While I expected to see an approximately
50% reduction in EDN1 secretion due to half of the number of mesenchymal HCC4006GeR cells seeded in the 50/50 admix compared to HCC4006Ge-R pure culture, I found a
significantly lower EDN1 concentration in the 50/50 admix. It is possible that in HCC4006
cell lines, EDN1 secreted by mesenchymal cells is taken up by epithelial cells leading to
increased VEGF-A secretion. This result was not replicated in a comparison between
epithelial HCC827 and mesenchymal ER23 cell lines. In these cell lines, a 50/50 admix
produced VEGF-A concentrations similar to epithelial cells alone and EDN1
concentrations approximately 50% of that of mesenchymal cells alone. Based on this result
we used HCC827 and ER23 cell lines for our admix in vivo studies.
It was unclear whether this change in secretion was an early or late event in the
EMT process, therefore I measured factors secreted by epithelial HCC4006 cells treated
with short-term (72 hours) 100nM gefitinib treatment. I found that 72 hours of gefitinib
treatment was sufficient to produce the switch from primarily VEGF-A secretion to
primarily EDN1 secretion (Figure 5E). I therefore conclude that the switch from VEGF-A
secretion to EDN1 secretion represents either an early effect of the EMT process or a direct
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consequence of EGFR inhibition. These events may be linked considering short-term
EGFR inhibition has been shown to induce TGF-β expression which can result in
EMT[55]. I believe that EGFR TKI treatment primes the cell for the switch from VEGF-A
secretion to EDN1 secretion during the EMT process. This change in expression may result
in greater tumor neo-angiogenesis providing a possible explanation of why admix tumors
show a growth advantage in vivo.
Using in vitro tube formation assay, I determined the effect of VEGF-A and EDN1
on endothelial cell differentiation. By depositing endothelial HUVEC cells onto a reducedgrowth factor Matrigel coated plate, I exposed endothelial cells to conditioned media
produced from epithelial, mesenchymal or admix cell cultures. By measuring the formation
of tube structures I can measure the ability of conditioned media to induce differentiation in
endothelial cells. I found that conditioned media produced from admix culture conditions
induced greater tube structure compared to epithelial or mesenchymal cells alone (Figure
6A). By utilizing the ImageJ angiogenesis analyzer plugin[107], I objectively quantified
several parameters useful for assessing the differentiation of endothelial cells. I focus on
total tubule length, node count, and mesh area. The total tubule length measurement is an
indicator of overall differentiation level. The node count parameter is analogous to the
sprouting step of in vivo angiogenesis in which endothelial cells differentiate to establish an
outgrowth from an established blood vessel. Mesh area is analogous to the ability for newly
established blood vessels to join with already established blood vessel structures in vivo and
therefore represents the highest-order organization of blood vasculature structure. I found
that conditioned media from admix culture conditions showed a significant increase in total
tubule length, node count, and mesh area. I therefore conclude that admix conditions
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induces greater endothelial cell differentiation compared to epithelial or mesenchymal pure
culture conditions in vitro (Figure 6B).
To test if the presence of both VEGF-A and EDN1 could explain the increased
endothelial cell differentiation seen in our conditioned media experiment in vitro, I
performed the tube formation assay using exogenous recombinant VEGF-A and EDN1
(Figure 7A). I found that the addition of both of these factors was sufficient to produce a
trend toward a greater tube formation morphology compared to either factor alone or basal
media conditions. Our ImageJ quantification of this experiment lacks mesh area due to the
overall lower tube formation compared to the conditioned media experiment. The addition
of both factors did not produce a significant increase in total tube length and node count
although a clear trend is present (Figure 7B). I rationalize this by acknowledging the diverse
population of unknown growth factors that may be present in conditioned media. While
VEGF- A and EDN1 secretion is an important component to this population, it likely does
not represent the only EMT-mediated change in growth factor secretion important in blood
vasculature regulation. Indeed I observed an up-regulation of several other angiogenesisrelated growth factors in our cell lines such as FGF-2 or angiopoietin-2 upon the EMT
process (Figure 4). While these factors were only shown be up-regulated in HCC4006 and
HCC827 cell lines respectively, it is possible these factors individually contribute to
endothelial cell differentiation. Additionally, I recognize that our conditioned media
preparation is somewhat of a black box in which unmeasured factors may be contributing to
VEGF-A/EDN1-mediated endothelial cell differentiation.
I then sought to test whether the VEGF-A/EDN1 signaling systems were targetable
by drugs known in the field to inhibit the involved receptors for these factors. To this end, I
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utilized the VEGFR2 inhibitor sunitinib and the EDNRA specific inhibitor Zibotentan.
Sunitinib is a potent multi- target inhibitor sold under the trade name Sutent by Pfizer Inc.
It was first approved for use in renal cell carcinoma and imatinib-resistant gastrointestinal
stromal tumors on January 26, 2006. Sunitinib is able to inhibit all receptors for plateletderived growth factor and all VEGF species receptors. Sunitinib has also been shown to
inhibit the receptor tyrosine kinase CD117 (c-KIT)[105]. Zibotentan is an EDNRA specific
inhibitor developed by AstraZeneca for use in the treatment of prostate cancer. The drug
failed a phase III clinical trial for prostate cancer and has since been discontinued after
failing to show any survival benefit to patients[118]. I chose to use Zibotentan due to its
EDNRA- specific activity and the efficacy of the drug for inhibiting EDNRA signaling in
vitro. Because a sufficiently high concentration of either of these drugs can effectively
inhibit tube formation by conditioned media, I must establish low-dose concentrations of
each drug in order to examine the benefit of dual therapy. I found that 10nM sunitinib and
100nM Zibotentan failed to significantly inhibit tube formation induced by admix cell
culture conditioned media when used alone. In contrast, the combination treatment at these
concentrations significantly abrogated tube formation as measured by ImageJ
quantification of node count, total tubule length and mesh area (Figure 8). These results
suggest that the dual treatment of sunitinib/Zibotentan sufficient to abrogate the additive
effect these growth factors have on endothelial cell differentiation. In order to test if our
low dose 10nM sunitinib treatment was effectively able to abrogate VEGF-A mediated
signaling, I examined the effect of stimulation by conditioned media produced from admix
culture conditions on HUVEC cells. I exposed HUVEC cells to admix conditioned media
for 8 hours and complete EGM media either alone or with 10nM sunitinib. I found that
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admix conditioned media effectively up-regulated phosphorylated VEGFR2 as expected.
Furthermore, the addition of 10nM sunitinib was sufficient to down-regulate
phosphorylated VEGFR in admix conditioned media or EGM conditions. These results
suggest 10nM sunitinib is an effective concentration for the inhibition of VEGFR2 in
HUVEC cells (Figure 9). This result supports our dual VEGFR2/EDNRA inhibition tube
formation assay. Since I am able to effectively reduce phosphorylated VEGFR2 by 10nM
sunitinib treatment, tube formation seen under single target sunitinib treatment must be due
to other growth factors present in admix conditioned media; possibly EDN1. This result
highlights the importance of multiple signaling pathways in the induction of a tube
formation morphology in vitro. I also examined EDNRA expression and found that
EDNRA is down-regulated after 8 hours in basal EBM media unstimulated conditions.
EDNRA expression was seen to be comparable among stimulated conditions with or
without sunitinib treatment. Since EDNRA activation opens the L-type Ca2+ channel
resulting in the influx of Ca2+ to the cytosol, the quantification of intracellular Ca2+
concentration using flow cytometry is commonly accepted as an assay to assess EDNRA
activation by the EDN1 stimulation[119]. In order to exclude other Ca2+ channel activators
present in conditioned media, I will need to perform the assay to evaluate if recombinant
EDN1 would activate EDNRA in vascular endothelial cells and if the activation can be
abrogated by 100nM Zibotentan treatment.
In order to study the specific effects of EDN1 in the tumor microenvironment in
vivo, I produced epithelial HCC827 cell lines ectopically expressing EDN1 or Flag/V5
control. I confirmed VEGF-A secretion was maintained by Luminex analysis (Figure
10A). To our surprise, tumors grown from HCC827 EDN1 over-expressing cells showed a
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significant growth retardation compared to HCC827 Flag/V5 cells (Figure 10B). This
result forced us to reconsider the effect of EDN1 in the tumor microenvironment. I have
shown that EDN1 secretion is up-regulated in cells with a mesenchymal phenotype, and it
is well known that tumors harboring a mesenchymal sub-population are significantly more
resistant to EGFR TKI treatment[57]. I therefore hypothesized that EDN1 secretion in the
tumor microenvironment may be contributing to drug resistance. While EDN1 secretion
has been linked to increased MVD in several tumor types including ovarian carcinoma[69]
and chondrosarcoma[84], the opposite has been found in castration-resistant prostate
cancer[85] and some melanomas[86]. The decreased tumor growth in these cancers were
attributed to the vasoconstrictive properties of EDN1 preventing sufficient blood flow to
the tumor. If this is also true in a NSCLC model, it would explain why EDN1 overexpressing tumors show significant growth retardation. Upon drug treatment, the
decreased MVD would become beneficial to the tumor by limiting drug perfusion within
the tumor. I hypothesized that the vasconstrictive property of EDN1 was contributing to
EGFR TKI resistance in our NSCLC model.
Therefore, I returned to our epithelial HCC827, mesenchymal ER23 and admix
condition xenograft model. Upon 6-day gefitinib treatment, I observed significantly greater
residual tumor volume in admix and mesenchymal tumors compared to epithelial (Figure
11B). I hypothesize that EDN1 is limiting blood supply to the tumor therefore limiting the
growth of the epithelial component of admix tumors. Since epithelial cells are the main
contributor to VEGF-A secretion, EDN1 could exert an anti-angiogenic effect on admix
tumors. Additionally, upon EGFR TKI treatment, epithelial cells switch from VEGF-A
secretion to EDN1 secretion (Figure 5E). I believe this also occurs within admix tumors but
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the presence of constitutively EDN1 secreting mesenchymal cells may prime the tumor to
competently constrict the relevant vasculature to prevent drug perfusion.
To test if EGFR TKI resistance was due to EDN1 secretion, I subjected our
HCC827 EDN1 over-expression xenografts to a 6-day gefitinib treatment and measured
residual tumor volume by caliper measurement. HCC827 EDN1 expressing tumors were
allowed to reach the same volume as Flag/V5 control prior to treatment. I found that
HCC827 EDN1 over-expressing tumors showed significantly greater residual tumor
volume compared to HCC827 Flag/V5 following gefitinib treatment (Figure 11D). As
expected, EDN1 over-expressing cells showed no significant increase in gefitinib
resistance in vitro (Figure 11C). This further implicated the host vasculature in EDN1mediated EGFR TKI resistance. If EDN1 was acting to decrease MVD in our NSCLC
model, I would expect a lower MVD in admix tumors. Indeed I observed that MVD was
significantly reduced in admix and mesenchymal tumors compared to epithelial (Figure
12A). In order to determine if this effect was due to EDN1 secretion, I established
mesenchymal HCC4006Ge-R cell lines expressing a shRNA knockdown of EDN1 or nontarget control. A murine xenograft was performed and CD31 staining was conducted on
the resulting tumors. I found that EDN1-competent HCC4006Ge-R shNT cells grown in
admix with epithelial HCC4006 cells show significantly lower blood vessel density
compared to HCC4006 alone. This effect can be abrogated through the knockdown of
EDN1 in mesenchymal HCC4006Ge-R cells grown in admix with HCC4006 cells (Figure
12B). This result further supports the hypothesis that EDN1 secretion within the tumor
microenvironment is contributing to MVD depression. If this were true, I would expect
gefitinib penetrance to be decreased in tumors with an EDN1-secreting component.
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To indirectly assess the penetrance of EGFR TKIs in epithelial, mesenchymal and
admix tumors, I measured total EGFR expression as well as the phosphorylation of EGFR
in these tumors by IHC staining. I found that EGFR is expressed at comparable levels in
untreated epithelial, mesenchymal or admix tumors. Epithelial tumors treated with gefitinib
showed wide-scale destruction of tumor structure as well as a down regulation of EGFR
expression. Conversely, mesenchymal and admix tumors showed a maintenance of EGFR
expression upon gefitinib treatment (Figure 14). The phosphorylation of EGFR serves as a
pharmacodynamics marker of EGFR activity and the effectiveness of inhibition by EGFR
TKIs[114]. Therefore, I performed IHC staining for phosphorylated EGFR in untreated and
treated epithelial, mesenchymal or admix tumors to indirectly assess the penetrance of
EGFR TKIs in the tumors. I observed that gefitinib treatment abrogated the phosphorylated
EGFR signal in epithelial tumors suggesting the availability of gefitinib was sufficient to
inhibit EGFR activity. Interestingly, both mesenchymal and admix tumors maintained
phosphorylated EGFR following gefitinib treatment (Figure 13). Since both mesenchymal
and epithelial cells harbor mutated EGFR that is constitutively active and exquisitely
sensitive to EGFR TKIs, an insufficient amount of EGFR inhibitor may available in these
tumors to fully suppress the EGFR phosphorylation. Surprisingly, I found that admix
tumors are epithelial phenotype dominated (Figure 3). Since tumors grown from epithelial
cells alone show exquisite sensitivity to EGFR TKIs, I conclude that the drug is not
thoroughly penetrating these tumors. In order to test if poor EGFR TKI penetrance in the
tumors is caused by the presence of EDN1, tumor samples need to be tested for
intratumoral gefitinib concentration using mass spectrometry. To this end I have sent tumor
chip samples to our collaborators for mass spectrometry analysis. I expect to find a
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significantly decreased concentration of gefitinib in mesenchymal and admix conditions
compared to epithelial as well as decreased gefitinib concentrations in EDN1 overexpressing tumors compared to Flag/V5 controls. I exclude the possibility of gefitinibmediated EMT in drug treated tumors due to the short time period in which the drug
treatment took place. In the clinic, EMT normally arises from EGFR TKI treatment over a
period of ~6 months. Since our drug treatment period was limited to 6 days, this excludes
the possibility that drug resistance could be explainable by gefitinib-mediated EMT.
I believe the growth advantage of admix conditions to not be explainable by the
presence of EDN1 secreting cells within admix conditions. Indeed, tumors grown from
HCC827 EDN1 over- expressing cells showed a significant growth retardation compared
to HCC827 Flag/V5 cells (Figure 10B). I believe I did not capture the growth advantage of
admix conditions in vitro because of the normoxic conditions used. Factors secreted by
mesenchymal cells may show differential effects in the relatively hypoxic conditions
present in vivo. Marek et al. described an autocrine feedback loop between epithelial and
mesenchymal NSCLC cell lines involving the FGF-2 signaling pathway[120]. I also
observed an up-regulation of FGF-2 in our mesenchymal HCC4006Ge-R cells compared
to epithelial HCC4006 cells (Figure 4). Additionally, FGF-2 expression is well known to
be up-regulated under hypoxic conditions[121]. I speculate that under hypoxic conditions,
I may have observed a growth advantage in vitro in admix conditions compared to
epithelial or mesenchymal pure cultures.
The in vitro tube formation assay inherently excludes the effect of vasoconstriction
due to the lack of the smooth muscle that normally sheaths mature blood vessels in vivo.
Therefore, the assay isolates the pro-differentiation capabilities of VEGF-A and EDN1 on
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endothelial cells. In light of this realization, it makes sense that our in vitro results did not
support our in vivo results. If only considering our in vitro results, I would propose that
EDNRA inhibition may be an important addition to VEGFR2 inhibition-based treatment
regimens due to the pro-angiogenic nature of EDN1 contributing to increased MVD in the
tumor. Given that VEGFR2 inhibition in NSCLC clinical trials has been largely
ineffective, I would pose that the switch between VEGF-A secretion to EDN1 secretion
during EMT or EGFR TKI treatment (Figure 5A-E) represents an escape mechanism to
VEGFR2 inhibition. In light of our in vivo results, I recommend EDNRA inhibition as an
effective addition to a blood vascular-based approach to NSCLC treatment not to inhibit
angiogenesis but to increase MVD leading to increased EGFR TKI tumor penetrance
(Figure 12,14).
It has been previously shown that EDN1 can have differential effects on the blood
vasculature depending on the tissue in which the tumor arose[69, 84-86]. It has been posed
by previous researchers that EDN1 concentrations typically secreted by tumor cells may
not be sufficient alone to overcome the vasoconstrictive effect of EDN1 and cause a proangiogenic effect. Therefore, the contribution of surrounding normal tissue to increasing
EDN1 concentration cannot be ignored. It may be that in tissues which normally secrete
high levels of EDN1, tumor cells secreting EDN1 have a pro-angiogenic effect whereas in
tissues which are normally EDN1 poor, secretion of EDN1 has an anti-angiogenic effect.
Therefore, a limitation of this study is that it is limited to sub-cutaneous xenograft models.
The blood vasculature in the subcutaneous space is limited compared to that of the lung.
Additionally the expression of EDN1 in the lung is known to be higher than that of the subcutaneous space. In order to properly study the effect of EDN1 on the tumor vasculature in
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the native environment of the lung, I propose performing an intrapulmonary injection of
epithelial, mesenchymal and admix tumor cell lines. I hypothesize that in a tissue of high
native EDN1 expression, the effect of EDN1 may be pro- angiogenic.
I conclude by hypothesizing a model incorporating the vasoconstrictive properties of
EDN1 into our observed MVD depression in EDN1-secreting tumors. I believe that in a
purely epithelial tumor, the secretion of VEGF-A competently induces tumor neoangiogenesis leading to tumor growth while maintaining vasodilation in the blood
vasculature. Upon gefitinib treatment, the dilated properties of the tumor blood vasculature
allow for the drug to fully penetrate the tumor allowing for maximal efficacy and significant
tumor reduction. Although I have shown that short-term gefitinib treatment is sufficient to
induce EDN1 secretion in epithelial cells, I hypothesize that this event does not occur fast
enough to prevent significant tumor reduction. In a tumor completely composed of
mesenchymal cells, the lack of VEGF-A secretion prevents tumor neo-angiogenesis while
the secretion of EDN1 causes existing blood vasculature to become constricted. Together,
this leads to a relatively small tumor unable to grow above a certain threshold. Upon gefitinib
treatment, the limited and vasoconstricted blood vasculature results in poor drug penetrance
leading to the observed drug resistance. In 50/50 admix conditions, the presence of EDN1 in
the tumor microenvironment leads to vasoconstriction above basal levels while the presence
of VEGF-A allows for enough tumor neo-angiogenesis to result in overall tumor growth.
Upon gefitinib treatment, the presence of EDN1-secreting mesenchymal cells cause the
protection of the epithelial cell component allowing the epithelial cells enough time to switch
from VEGF-A secretion to EDN1 secretion. This high level of EDN1 secretion is then
sufficient to induce additional vasoconstriction in the tumor blood vasculature further
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preventing drug penetrance and leading to the observed drug resistance.

Figure 15. Model Illustrating Hypothesis Relating EDN1-Mediated Vasoconstriction to
Drug Resistance and Reduced MVD

In summary, angiogenesis in NSCLC has been identified as important therapeutic
target in combination with EGFR TKIs. However, only small incremental advancements have
been made for the use of angiogenesis inhibitors in NSCLC and it remains elusive why the
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inhibition of VEGF-mediated neovascularization is not therapeutically efficacious. I present
experimental evidence that a subpopulation of NSCLC cells with EGFR TKI-induced EMT
contributes toward the attenuation of the response to EGFR TKI therapy. One of the hallmarks
of cancer is heterogeneity and I have previously demonstrated that tumor heterogeneity
within NSCLC cells lines harboring EGFR kinase domain mutations gives rise to divergent
resistance mechanisms in response to treatment. In vivo admix models are instructive in
studying intratumoral heterogeneity and in elucidating therapeutic responses and tumor-host
interactions. While NSCLC cells with acquired EGFR TKI resistance and EMT phenotype
did not exhibit growth advantage in vitro, a 50% epithelial EGFR TKI sensitive and 50%
mesenchymal EGFR TKI resistant admix provided significant growth advantage in vivo
assessed by caliper measurement. This preliminary result led us to hypothesize that changes
in angiogenic growth factor expression during the EMT process might lead to the in vivo
growth advantage I observed. To test the hypothesis, I utilized the Luminex multiplex assay
system to quantify secreted growth factors, cytokines, and chemokines important in
angiogenesis. I have discovered that epithelial EGFR TKI sensitive cells secrete a significant
amount of VEGF-A and cells with acquired/transient EGFR TKI resistance with an EMT
phenotype secrete substantial amount of EDN1. Using an in vitro tube formation assay, I
showed that secreted VEGF-A and EDN1 in admix conditions work synergistically to
promote endothelial cell differentiation. Furthermore, this synergistic effect can be
attenuated by VEGFR2/EDNRA dual inhibition. Surprisingly, ectopic overexpression of
EDN1 in EGFR- mutated HCC827 cells resulted in significant growth retardation in vivo.
Informed by a literature search, I hypothesized that the presence of EDN1 in the tumor
microenvironment contributes positively to EGFR TKI resistance, possibly through the
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vasoconstrictive property of EDN1. I observed that epithelial/mesenchymal admix tumors
and ectopic overexpression of EDN1 in EGFR-mutated HCC827 cells conferred
significantly more resistance to gefitinib in vivo. This result led us to hypothesize that the
vasoconstrictive properties of EDN1 may reduce MVD in EGFR-mutated NSCLC tumors
leading to poor EGFR TKI penetrance in vivo. I tested this through CD31 IHC staining and
MVD calculation. I tested poor EGFR TKI penetrance indirectly by examining
phosphorylated EGFR and found maintenance of the signal in admix and mesenchymal
tumors. Taken together, I suggest that inhibition of the EDN1 signaling system may be an
important component to a blood vascular-based approach to treatment of EGFR-mutation
positive NSCLC when given as an adjuvant therapy to EGFR TKI treatment.
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